Minerva Neurosciences (NERV) 10-K 26 Mar 15 2014 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 31, 2014	Mar. 20, 2015	Jun. 30, 2014
Document Entity Information [Abstract]
Entity Registrant Name	Minerva Neurosciences, Inc.
Entity Central Index Key	1598646
Current Fiscal Year End Date	-19
Entity Filer Category	Smaller Reporting Company
Document Type	10-K
Document Period End Date	31-Dec-14
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY
Amendment Flag	FALSE
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Public Float			$0
Entity Common Stock, Shares Outstanding		24,721,143

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2014	Dec. 31, 2013
Current assets
Cash and cash equivalents	$18,545,702	$1,818,317
Restricted cash	35,014
Prepaid expenses	756,979	852
Total current assets	19,337,695	1,819,169
Equipment, net	43,446	3,232
In-process research and development	34,200,000	19,000,000
Goodwill	14,869,399	7,918,387
Deferred public offering costs		433,998
Total assets	68,450,540	29,174,786
Current liabilities
Accounts payable	641,813	522,981
Accrued expenses and other current liabilities	1,645,258	815,239
Accrued collaborative expenses	1,222,420
Convertible promissory notes		58,270
Derivative liability		10,093
Total current liabilities	3,509,491	1,406,583
Deferred taxes	13,433,760	7,588,600
Other noncurrent liabilities	7,694
Total liabilities	16,950,945	8,995,183
Commitments and contingencies
Stockholders’ equity
Preferred stock; $.0001 par value; 100,000,000 shares authorized; none issued or outstanding as of December 31, 2014 and 2013, respectively
Common stock; $.0001 par value; 125,000,000 shares authorized; 18,439,482 and 6,112,738 shares issued and outstanding as of December 31, 2014 and 2013, respectively	1,844	611
Additional paid-in capital	126,228,981	38,008,783
Accumulated deficit	-74,731,230	-17,829,791
Total stockholders’ equity	51,499,595	20,179,603
Total liabilities and stockholders’ equity	$68,450,540	$29,174,786

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Statement Of Financial Position [Abstract]
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, shares authorized	100,000,000	100,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized	125,000,000	125,000,000
Common stock, shares issued	18,439,482	6,112,738
Common stock, shares outstanding	18,439,482	6,112,738

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Expenses
Research and development	$42,908,566	$708,489
General and administrative	11,961,865	2,466,490
Total expenses	54,870,431	3,174,979
Loss from operations	-54,870,431	-3,174,979
Foreign exchange gains (losses)	18,727	-28,977
Interest (expense) income	-2,049,735	-58,049
Net loss	($56,901,439)	($3,262,005)
Net loss per share, basic and diluted	($4.47)	($0.78)
Weighted average shares outstanding, basic and diluted	12,724,395	4,186,104

Consolidated_Statements_of_Sto

Consolidated Statements of Stockholders' Equity (USD $)	Total	Common Stock	Additional Paid-In Capital	Accumulated Deficit
Balance at Dec. 31, 2012	$19,019	$356	$14,586,449	($14,567,786)
Balance (in shares) at Dec. 31, 2012		3,562,454
Increase (Decrease) in Stockholders' Equity
Sale of common stock for cash at $3.50 per share	1,850,000	53	1,849,947
Sale of common stock for cash at $3.50 per share (in shares)		528,576
Issuance of shares for business acquisition	18,943,366	200	18,943,166
Issuance of shares for business acquisition (in shares)		1,997,192
Beneficial conversion feature--convertible debt	1,973,500		1,973,500
Issuance of common stock to a consultant	232,534	2	232,532
Issuance of common stock to a consultant (in shares)		24,516
Stock-based compensation	423,189		423,189
Net loss	-3,262,005			-3,262,005
Balances at Dec. 31, 2013	20,179,603	611	38,008,783	-17,829,791
Balance (in shares) at Dec. 31, 2013		6,112,738
Increase (Decrease) in Stockholders' Equity
Issuance of shares for business acquisition	16,541,834	148	16,541,686
Issuance of shares for business acquisition (in shares)		1,481,583
Issuance of common stock pursuant to an initial public offering and concurrent private placements, net of issuance costs	51,600,986	956	51,600,030
Issuance of common stock pursuant to an initial public offering and concurrent private placements, net of issuance costs (in shares)		9,566,557
Vesting of common shares issued	10,542,670	93	10,542,577
Vesting of common shares issued (in shares)		926,604
Stock-based compensation	7,423,941		7,423,941
Conversion of debt and interest to common stock	2,112,000	36	2,111,964
Conversion of debt and interest to common stock (in shares)		352,000
Net loss	-56,901,439			-56,901,439
Balances at Dec. 31, 2014	$51,499,595	$1,844	$126,228,981	($74,731,230)
Balance (in shares) at Dec. 31, 2014		18,439,482

Consolidated_Statements_of_Sto1

Consolidated Statements of Stockholders' Equity (Parenthetical) (USD $)	Dec. 31, 2013
Statement Of Stockholders Equity [Abstract]
Sale of common stock, price per share	$3.50

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Cash flows from operating activities:
Net loss	($56,901,439)	($3,262,005)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	33,869
Amortization of debt discount recorded as interest expense	1,952,309	36,231
Stock-based compensation expense	17,966,611	655,723
Unrealized foreign exchange loss		22,039
Change in fair value of derivative	-10,093	117
Changes in operating assets and liabilities
Prepaid expenses	-713,200	8,143
Accounts payable	368,698	522,981
Accrued expenses and other liabilities	112,285	-143,472
Accrued collaborative expenses	1,222,420
Other noncurrent liabilities	7,694
Net cash used in operating activities	-35,960,846	-2,160,243
Cash flows from investing activities:
Cash acquired in business combination	1,167,869
Restricted cash	-35,014
Purchases of equipment	-45,609	-3,232
Net cash provided by investing activities	1,087,246	-3,232
Cash flows from financing activities:
Cash acquired in business merger		631,478
Proceeds from issuance of convertible promissory notes		1,300,000
Proceeds from working capital loans	1,882,817
Repayments of working capital loans	-1,882,817
Proceeds from sales of common stock in initial public offering	31,334,702
Proceeds from sales of common stock in private placements	23,706,118	1,850,000
Fees paid in connection with private placements	-280,000
Public offering costs paid	-3,159,835
Net cash provided by financing activities	51,600,985	3,781,478
Net increase in cash and cash equivalents	16,727,385	1,618,003
Cash and cash equivalents
Beginning of period	1,818,317	200,314
End of period	18,545,702	1,818,317
Supplemental disclosure of noncash investing and financing activities
Common stock issued as consideration for business combination	16,541,834	18,943,366
Plus liabilities assumed:
Accrued expenses and other	321,417	334,423
ProteoSys milestone payable	681,600
Deferred tax liability	5,970,560	7,588,600
Convertible promissory notes		680,000
Derivative liability		3,476
Less assets acquired:
Prepaid expenses	42,926
Equipment	28,204
In-process research and development	15,200,000	19,000,000
Goodwill	7,076,412	7,918,387
Cash acquired in business merger	1,167,869	631,478
Deferred public offering costs included in accrued expenses and other liabilities		433,998
Beneficial conversion feature--convertible debt		1,973,500
Cash paid for interest	15,233
Conversion of debt and interest to common stock	$2,112,000

Nature_of_Operations_and_Liqui

Nature of Operations and Liquidity	12 Months Ended
	Dec. 31, 2014
Nature Of Operations And Liquidity Disclosure [Abstract]
Nature of Operations and Liquidity	NOTE 1 — NATURE OF OPERATIONS AND LIQUIDITY
	Nature of Operations
	Minerva Neurosciences, Inc. (“Minerva” or the “Company”), formerly known as Cyrenaic Pharmaceuticals Inc. (“Cyrenaic”) was incorporated on April 23, 2007. The Company is a biopharmaceutical company focused on the development of an experimental drug for the treatment of schizophrenia (discussed further in Note 6 — License Agreement). On November 12, 2013, Sonkei Pharmaceuticals, Inc. (“Sonkei”), a biopharmaceutical company focused on the development of an experimental drug for the treatment of depression and an affiliated company through certain common ownership, was merged into Cyrenaic with Cyrenaic being the surviving company. Subsequent to the merger, Cyrenaic changed its name to Minerva Neurosciences, Inc. In 2014 the Company formed Minerva Neurosciences Securities Corporation, a wholly-owned subsidiary.
	On February 11, 2014, the Company acquired Mind-NRG (discussed further in Note 3 — Business Combinations).  Mind-NRG is a Swiss development stage biopharmaceutical company focused on the development and commercialization of an experimental drug for the treatment of Parkinson’s disease. The Company acquired 100% of the share capital of Mind-NRG largely to obtain the intellectual property estate which underpins Mind-NRG’s lead product candidate, renamed MIN-301.
	On February 12, 2014, subject to the completion of an initial public offering (“IPO”), the Company entered into a co-development and license agreement (discussed further in Note 8 — Co-Development and License Agreement) pursuant to which the licensor granted the Company an exclusive license, in certain territories, under certain patent and patent applications to sell products containing any orexin 2 compound, controlled by the licensor and claimed in a licensor patent right, as an active ingredient, or MIN-202, for any use in humans. The license became effective on July 7, 2014 at the closing of the IPO and the payment of the $22.0 million license fee was made at that date.
	Going Concern
	The Company has limited capital resources and has incurred recurring operating losses and negative cash flows from operations since inception. As of December 31, 2014, the Company has an accumulated deficit of approximately $74.7 million. Management expects to continue to incur operating losses and negative cash flows from operations. The Company has financed its business to date from proceeds from the sale of common stock, loans and convertible promissory notes. On July 7, 2014, the Company sold shares in an IPO and two private placements resulting in proceeds to the Company of approximately $55.0 million.
	In January 2015 the Company entered into a loan and security agreement and drew down on $10.0 million in term loans.  In March 2015 the Company closed the sale of 6,281,661 shares of common stock and warrants to purchase an equal number of shares of common stock in a private placement resulting in net proceeds to the Company of $28.8 million (both discussed further in Note 15 – Subsequent Events).  The Company believes that based on its operating plan, cash on hand at December 31, 2014 and the proceeds from the term loans and the private placement in March 2015 will be sufficient to fund the Company’s operations through the end of 2016.
	The Company will need to raise additional capital in order to continue to fund operations and fully fund its clinical development programs. The Company believes that it will be able to obtain additional working capital through equity financings or other arrangements to fund operations; however, there can be no assurance that such additional financing, if available, can be obtained on terms acceptable to the Company.  If the Company is unable to obtain such additional financing, future operations would need to be scaled back or discontinued.
	The accompanying financial statements have been prepared as though the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

Significant_Accounting_Policie

Significant Accounting Policies	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Significant Accounting Policies	NOTE 2 — SIGNIFICANT ACCOUNTING POLICIES
	Basis of presentation
	The financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”), and include all adjustments necessary for the fair presentation of the Company’s financial position for the periods presented. From its inception, the Company has devoted substantially all of its efforts to business planning, engaging regulatory, manufacturing and other technical consultants, planning and executing clinical trials and raising capital.
	Consolidation
	The accompanying consolidated financial statements include the results of the Company and its wholly-owned subsidiaries, Mind-NRG SA and Minerva Neurosciences Securities Corporation.  Intercompany transactions have been eliminated.
	Significant risks and uncertainties
	The Company’s operations are subject to a number of factors that can affect its operating results and financial condition. Such factors include, but are not limited to: the results of clinical testing and trial activities of the Company’s products, the Company’s ability to obtain regulatory approval to market its products, competition from products manufactured and sold or being developed by other companies, the price of, and demand for, Company products, the Company’s ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products, and the Company’s ability to raise capital.
	The Company currently has no commercially approved products and there can be no assurance that the Company’s research and development will be successfully commercialized. Developing and commercializing a product requires significant time and capital and is subject to regulatory review and approval as well as competition from other biotechnology and pharmaceutical companies. The Company operates in an environment of rapid change and is dependent upon the continued services of its employees and consultants and obtaining and protecting intellectual property.
	Use of estimates
	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.
	Prior to the Company’s IPO, the Company utilized significant estimates and assumptions in determining the fair value of its common stock. The board of directors has determined the estimated fair value of the Company’s common stock based on a number of objective and subjective factors, including external market conditions affecting the biotechnology industry sector, discounted cash flows and the likelihood of achieving a liquidity event, such as an IPO of common stock or a sale of the Company.
	Research and development costs
	Costs incurred in connection with research and development activities are expensed as incurred. These costs include licensing fees to use certain technology in the Company’s research and development projects as well as fees paid to consultants and various entities that perform certain research and testing on behalf of the Company. The Company determines expenses related to clinical studies based on estimates of the services received and efforts expended pursuant to contracts with multiple research institutions and contract research organizations that conduct and manage clinical studies on its behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, the accrual is adjusted accordingly. The expenses for some trials may be recognized on a straight-line basis if the expected costs are expected to be incurred ratably during the period. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the consolidated financial statements as prepaid or accrued expenses.
	In July 2014, the Company paid a $22.0 million license fee, which has been included as a component of research and development expense since the licensed rights were not deemed to have an alternative future use. The Company accounts for the co-development and license agreement pursuant to which the license fee was paid as a joint risk-sharing collaboration in accordance with ASC 808, Collaboration Arrangements. Costs between the Company and the licensor with respect to each party’s share of development costs that have been incurred pursuant to the joint development plan are recorded within research and development expense or general and administrative expense, as applicable, in the accompanying consolidated financial statements due to the joint risk-sharing nature of the activities. The Company has included $1.2 million in accrued expenses as of December 31, 2014 related to this agreement.
	In-process research and development (“IPR&D”) assets represent capitalized incomplete research projects that the Company acquired through business combinations. Such assets are initially measured at their acquisition date fair values. The fair value of the research projects is recorded as intangible assets on the balance sheet, rather than expensed, regardless of whether these assets have an alternative future use.
	The amounts capitalized are being accounted for as indefinite-lived intangible assets, subject to impairment testing, until completion or abandonment of research and development efforts associated with the project. An IPR&D asset is considered abandoned when it ceases to be used (that is, research and development efforts associated with the asset have ceased, and there are no plans to sell or license the asset or derive defensive value from the asset). At that point, the asset is considered to be disposed of and is written off. Upon successful completion of each project, the Company will make a determination about the then remaining useful life of the intangible asset and begin amortization. The Company tests its indefinite-lived intangibles, IPR&D assets, for impairment annually on November 30 and more frequently if events or changes in circumstances indicate that it is more likely than not that the asset is impaired. When testing indefinite-lived intangibles for impairment, the Company may assess qualitative factors for its indefinite-lived intangibles to determine whether it is more likely than not (that is, a likelihood of more than 50 percent) that the asset is impaired. Alternatively, the Company may bypass this qualitative assessment for some or all of its indefinite-lived intangibles and perform the quantitative impairment test that compares the fair value of the indefinite- lived intangible asset with the asset’s carrying amount. There was no impairment of IPR&D for the years ended December 31, 2014 and 2013.
	Stock-based compensation
	The Company recognizes compensation cost relating to stock-based payment transactions in operating results using a fair-value measurement method, in accordance with ASC Topic 718 Compensation-Stock Compensation. ASC-718 requires all stock-based payments to employees, including grants of employee stock options, to be recognized in operating results as compensation expense based on fair value over the requisite service period of the awards. The Company determines the fair value of stock-based awards using the Black-Scholes option-pricing model which uses both historical and current market data to estimate fair value. The method incorporates various assumptions such as the risk-free interest rate, expected volatility, expected dividend yield, expected forfeiture rate and expected life of the options.
	Grants to non-employees are accounted for in accordance with ASC Topic 505-50 Equity — Based Payments to Non-Employees. The date of expense recognition is the earlier of the date at which a commitment for performance by the counterparty to earn the equity instrument is reached or the date at which the counterparty’s performance is complete. The Company determines the fair value of stock-based awards granted to non-employees similar to the way fair value of awards are determined for employees except that certain assumptions used in the Black-Scholes option-pricing model, such as expected life of the option, may be different and the fair value of each unvested award is adjusted at the end of each period for any change in fair value from the previous valuation until the award vests.
	Prior to the IPO, the Company utilized various valuation methodologies in accordance with the framework of the 2013 American Institute of Certified Public Accountants Technical Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation, to estimate the fair value of its common stock. The methodologies included a probability-weighted expected return methodology that determined an estimated value under an IPO scenario and a sale scenario based upon an assessment of the probability of occurrence of each scenario. Each valuation methodology includes estimates and assumptions that require the Company’s judgment. These estimates include assumptions regarding future performance, including the successful completion of preclinical studies and clinical trials and the time to complete an IPO or sale.
	Foreign currency transactions
	The Company’s functional currency is the US dollar. The Company pays certain vendor invoices in the respective foreign currency. The Company records an expense in US dollars at the time the liability is incurred. Changes in the applicable foreign currency rate between the date an expense is recorded and the payment date is recorded as a foreign currency gain or loss.
	Loss per share
	Basic loss per share excludes dilution and is computed by dividing net loss by the weighted-average number of shares of common stock outstanding for the period. Diluted loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that shared in the earnings of the entity.
	Income taxes
	The Company utilizes the liability method of accounting for income taxes as required by FASB ASC Topic 740 Income Taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax reporting bases of assets and liabilities and are measured using enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. Uncertain tax positions are evaluated in accordance with this topic and if appropriate, the amount of unrecognized tax benefits are recorded within deferred tax assets. Deferred tax assets are evaluated for realization based on a more-likely-than-not criterion in determining if a valuation allowance should be provided. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized.
	ASC Topic 740 also clarifies the accounting for uncertainty in income taxes recognized in the financial statements. The interpretation prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken, or expected to be taken, in a tax return. ASC Topic 740 provides guidance on the recognition of interest and penalties related to income taxes. There was no interest or penalties related to income taxes for the years ended December 31, 2014 and 2013. The Company has elected to treat interest and penalties, to the extent they arise, as a component of income taxes. Income tax years beginning in 2011 for federal and state purposes are generally subject to examination by taxing authorities, although net operating losses from all prior years are subject to examinations and adjustments for at least three years following the year in which the tax attributes are utilized.
	Concentration of credit risk
	Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash and cash equivalents. The Company maintains its cash and cash equivalent balances in the form of business checking accounts and money market accounts, the balances of which, at times, may exceed federally insured limits. Exposure to credit risk is reduced by placing such deposits with major financial institutions and monitoring their credit ratings.
	Cash and cash equivalents
	The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents.
	Equipment
	Equipment is stated at cost less accumulated depreciation. Equipment is depreciated on the straight-line basis over their estimated useful lives of three years. Expenditures for maintenance and repairs are charged to expense as incurred.
	Deferred public offering costs
	Deferred public offering costs included certain legal, accounting and other costs directly attributable to the Company’s proposed public offering of common stock. Upon completion of the initial public offering in 2014, these amounts were offset against the proceeds of the offering.
	Long-lived assets
	The Company reviews the recoverability of all long-lived assets, including the related useful lives, whenever events or changes in circumstances indicate that the carrying amount of a long-lived asset might not be recoverable. If required, the Company compares the estimated undiscounted future net cash flows to the related asset’s carrying value to determine whether there has been an impairment. If an asset is considered impaired, the asset is written down to fair value, which is based either on discounted cash flows or appraised values in the period the impairment becomes known. The Company believes that all long-lived assets are recoverable, and no impairment was deemed necessary at December 31, 2014 and 2013.
	Business Combinations
	For business combinations, the Company utilizes the acquisition method of accounting in accordance with ASC Topic 805, Business Combinations. These standards require that the total cost of an acquisition be allocated to the tangible and intangible assets acquired and liabilities assumed based their respective fair values at the date of acquisition. The allocation of the purchase price is dependent upon certain valuations and other studies. Acquisition costs are expensed as incurred. The Company recognizes separately from goodwill the fair value of assets acquired and the liabilities assumed. Goodwill as of the acquisition date is measured as the excess of consideration transferred and the acquisition date fair values of the assets acquired and liabilities assumed. While the Company uses its best estimates and assumptions as a part of the purchase price allocation process to accurately value assets acquired and liabilities assumed at the acquisition date, the Company’s estimates are subject to refinement. As a result, during the measurement period, which may be up to one year from the acquisition date, the Company may retroactively record adjustments to the fair value of the assets acquired and liabilities assumed, with the corresponding offset to goodwill. Upon the conclusion of the measurement period or final determination of the fair value of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded to the Company’s consolidated statements of operations.
	Goodwill
	The Company tests its goodwill for impairment annually, or whenever events or changes in circumstances indicate an impairment may have occurred, by comparing its reporting unit’s carrying value to its implied fair value. Impairment may result from, among other things, deterioration in the performance of the acquired business, adverse market conditions, adverse changes in applicable laws or regulations and a variety of other circumstances. If the Company determines that an impairment has occurred, it is required to record a write-down of the carrying value and charge the impairment as an operating expense in the period the determination is made. In evaluating the recoverability of the carrying value of goodwill, the Company must make assumptions regarding estimated future cash flows and other factors to determine the fair value of the acquired assets. Changes in strategy or market conditions could significantly impact those judgments in the future and require an adjustment to the recorded balances. The Company tested its goodwill for impairment as of November 30. There was no impairment of goodwill for the years ended December 31, 2014 and 2013.
	Fair value of financial instruments
	The Company provides disclosure of financial assets and financial liabilities that are carried at fair value based on the price that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value measurements may be classified based on the amount of subjectivity associated with the inputs to fair valuation of these assets and liabilities using the following three levels:
	Level 1 — Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.
	Level 2 — Inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (i.e., interest rates, yield curves, etc.) and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs).
	Level 3 — Unobservable inputs that reflect the Company’s estimates of the assumptions that market participants would use in pricing the asset or liability. The Company develops these inputs based on the best information available, including its own data.
	The following table presents information about the Company’s derivative liability as of December 31, 2013 measured at fair value on a recurring basis and indicates the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value:
		December 31, 2013
	In thousands	Total		Level 1		Level 2		Level 3
	Derivative liability:	$	10	$	—	$	—	$	10
	The derivative liability ceased upon the conversion of the convertible promissory notes into common stock in July 2014. The carrying amounts of cash, cash equivalents, accounts payable and accrued liabilities approximate fair value because of their short-term nature.
	Convertible Promissory Notes
	The Company’s convertible promissory notes at December 31, 2013 consisted of (i) $1.3 million face value convertible promissory notes, plus accrued interest of $15,671 and (ii) €518,519 face value convertible promissory notes, plus accrued interest of $8,605. The Euro denominated notes were acquired in conjunction with the merger with Sonkei (discussed further in Note 3 — Business Combinations), and recorded at their fair value of $680,000 on the date of the merger. At December 31, 2013, the fair market value of the convertible promissory notes was approximately $2.0 million. The carrying value of the convertible promissory notes at December 31, 2013 was $58,270, as a result of the beneficial conversion feature recorded at initial recognition as a debt discount.
	Discount Purchase Option
	The Company’s 8% convertible promissory notes contained an embedded derivative related to the conversion option containing a discount purchase feature in a qualified financing, as defined. The derivative is carried at fair value and is classified as Level 3 in the fair value hierarchy due to the use of significant unobservable inputs. The initial fair value of the derivative liability at the date of issuance in November 2013 was determined to be $9,976 using a probability-weighted valuation model applying the following assumptions: (i) discount rate of 8.0%, (ii) remaining term of approximately 7 months and (iii) the probabilities of conversion under various circumstances as at the date of measurement.
	As of December 31, 2013, the fair value of the derivative liability was determined to be $10,093 using a probability-weighted valuation model applying the following assumptions: (i) discount rate of 8.0%, (ii) remaining term of approximately 6 months and (iii) the probabilities of conversion under various circumstances as at the date of measurement. The $117 increase in the fair value of the derivative liability was recognized in interest expense as a loss on change in fair value of derivative liability for the year ended December 31, 2013.
	$3.50/€3.50 Conversion Option
	The Company’s 8% convertible promissory notes contained a beneficial conversion feature. The intrinsic value of the beneficial conversion feature was calculated by measuring the difference between the effective conversion price and the fair value of common stock at initial recognition. The Company recorded a debt discount for the fair value of the derivative, which was limited to the proceeds received of approximately $2.0 million, with an offsetting increase to additional paid-in capital. The beneficial conversion charge has been included in the balance sheet at December 31, 2013 as a discount to the related convertible promissory notes. The discount was accreted as non-cash interest expense over the expected term of the debt (June 30, 2014) using the effective interest method, which totaled $2.0 million and $36,231 for the years ended December 31, 2014 and 2013, respectively.
	Segment information
	Operating segments are defined as components of an enterprise (business activity from which it earns revenue and incurs expenses) about which discrete financial information is available and regularly reviewed by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company’s chief decision maker, who is the Chief Executive Officer, reviews operating results to make decisions about allocating resources and assessing performance for the entire Company. The Company views its operations and manages its business as one operating segment.
	Recent Accounting Pronouncements
	In June 2014 the Financial Accounting Standards Board (FASB) issued Accounting Standards Update 2014-10 Development Stage Entities (Topic 915) Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities.  The amendments in this Update 2014-10 removed the definition of a development stage entity from the Master Glossary of the Accounting Standards Codification, thereby removing the financial reporting distinction between development stage entities and other reporting entities from U.S. GAAP. In addition, the amendments eliminated the requirements for development stage entities to (1) present inception-to-date information in the statements of income, cash flows, and shareholder equity, (2) label the financial statements as those of a development stage entity, (3) disclose a description of the development stage activities in which the entity is engaged and (4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage. The Company adopted this pronouncement in 2014 and has eliminated the above mentioned disclosures.
	From time to time, new accounting pronouncements are issued by FASB and are adopted by the Company as of the specified effective date. The Company believes that the impact of other recently issued but not yet adopted accounting pronouncements will not have a material impact on the consolidated financial position, consolidated results of operations, and consolidated cash flows, or do not apply to the Company.

Business_Combinations

Business Combinations	12 Months Ended
	Dec. 31, 2014
Business Combinations [Abstract]
Business Combinations	NOTE 3 — BUSINESS COMBINATIONS
	Mind-NRG
	On February 11, 2014, the Company acquired Mind-NRG, a Swiss development stage biopharmaceutical company focused on the development and commercialization of an experimental drug for the treatment of Parkinson’s Disease. This transaction was treated as a business combination by the Company. The purchase price was 1,481,583 shares of the Company’s common stock with an estimated fair value of $11.17 per share, or approximately $16.5 million. The Company acquired 100% of the share capital of Mind-NRG largely to obtain the intellectual property estate which underpins Mind-NRG’s lead product candidate NRG-101, renamed MIN-301.
	The fair value of the Company’s common stock issued was determined based on a number of objective and subjective factors, including external market conditions affecting the biotechnology industry sector, discounted cash flows and the likelihood of achieving a liquidity event, such as an IPO or a sale of the Company. The purchase price allocation was based upon an analysis of the fair value of the assets and liabilities acquired from Mind-NRG. Identifying the fair value of the tangible and intangible assets and liabilities acquired required the use of estimates by management, and were based upon currently available data, as noted below.
	—	The fair value of current assets and liabilities approximated their book value.
	—	The Company measured the value of the acquired IPR&D using the income approach — multi period excess earnings method and assembled workforce using the cost approach (for contributory asset charge calculations). The multi-period excess earning method measures the present value of the future earnings expected to be generated during the remaining lives of the subject assets.
	—	The Company recorded a deferred tax liability for the difference in the book and tax basis of the IPR&D, multiplied by the effective income tax rate.
	The establishment of the fair value of the consideration for an acquisition, and the allocation to identifiable tangible and intangible assets and liabilities requires the extensive use of accounting estimates and management judgment. The fair values assigned to the assets acquired and liabilities assumed are from estimates and assumptions based on data currently available.
	The Company allocated the excess of purchase price over the identifiable intangible and net tangible assets to goodwill. The goodwill recorded recognizes the value of the overall development program, including both the current pre-clinical development program in process and the future clinical trial development strategy. Such goodwill is not deductible for tax purposes. The aggregate consideration of $16.5 million has been allocated to assets acquired and liabilities assumed based on estimated fair values at December 31, 2013 as follows:
	Cash		$	1,167,869
	Other assets			71,130
	Goodwill			7,076,412
	In-process research and development			15,200,000
	Deferred tax liability			(5,970,560	)
	Accrued expenses			(321,417	)
	ProteoSys milestone payable			(681,600	)
			$	16,541,834
	IPR&D, an indefinite-lived asset, is included as an asset on the Company’s balance sheet until such time that: (i) a marketing approval to commercially sell the drug is received from a regulatory agency, in which case it will be amortized over its expected commercial life, or (ii) such time as the IPR&D is deemed to be impaired, in which case it will be expensed. The transaction is being treated as a stock purchase for income tax purposes and accordingly, the tax bases of Mind-NRG’s assets and liabilities are not adjusted for the effect of purchase accounting.
	Sonkei
	On November 12, 2013, Cyrenaic merged with Sonkei, with Cyrenaic being the survivor company. Each share of Sonkei common stock was converted into 0.383 shares of Cyrenaic common stock, resulting in the issuance of 2,423,368 shares. There were certain common stockholders between Sonkei and Cyrenaic, however, since the underlying investors in the venture funds were not “substantially similar”, the merger was accounted for as a business combination with Cyrenaic being treated as the acquirer. The results of Sonkei are included in the accompanying financial statements commencing November 12, 2013. The Company merged with Sonkei in order to acquire Sonkei’s lead product candidate, MIN-117.
	At the date of the merger, a Sonkei non-employee held 1,112,500 shares of Sonkei common stock with a nonrecourse note due to Sonkei, which was being treated as a stock option for accounting purposes. In connection with the merger, the Company issued 426,176 shares to the holder with a nonrecourse note (discussed further in Note 8 — Stockholders’ Equity) in order to replace the holder’s stock options in Sonkei. Due to the nonrecourse note, these shares of the Company are treated as stock options for accounting purposes and the holder of the option can only vest in the stock options if the holder continues to provide services to the Company through the time of a change in control, as defined. In summary, the Company issued replacement stock options of the Company for the old Sonkei stock options. As a change in control was not deemed probable as of the merger date, the options were not included as part of the consideration transferred in the merger accounting. Accordingly, the Company will recognize all of the compensation expense for these stock options in the statement of operations once achievement of the performance condition becomes probable. The merger accounting purchase price was therefore determined based upon the common stock shares issued of 1,997,192 at a valuation of $9.49 per common share for a total purchase price of approximately $18.9 million. Merger expenses of $14,000 were included in general and administrative expenses for the year ended December 31, 2013.
	The fair value of the Company’s common stock issued was determined based on a number of objective and subjective factors, including external market conditions affecting the biotechnology industry sector, discounted cash flows and the likelihood of achieving a liquidity event, such as an IPO or a sale of the Company. The purchase price allocation was based upon an analysis of the fair value of the assets and liabilities acquired from Sonkei. Identifying the fair value of the tangible and intangible assets and liabilities acquired required the use of estimates by management, and were based upon currently available data, as noted below.
	—	The fair value of current assets and liabilities approximated their book value.
	—	The fair value of the convertible promissory notes was determined based upon a number of factors including (i) interest rate, (ii) creditworthiness of the Company, (iii) the applicable foreign exchange rate and (iv) the conversion features (described in Note 7 — Convertible Promissory Notes). The face amount of the note acquired is €518,519 (approximately $0.7 million at November 12, 2013).
	—	The Company measured the value of the acquired IPR&D using the income approach — multi period excess earnings method and assembled workforce using the cost approach (for contributory asset charge calculations). The multi-period excess earning method measures the present value of the future earnings expected to be generated during the remaining lives of the subject assets.
	—	The Company recorded a deferred tax liability for the difference in the book and tax basis of the IPR&D, multiplied by the effective income tax rate.
	The Company allocated the excess of purchase price over the identifiable intangible and net tangible assets to goodwill. The goodwill recorded recognizes the synergies and value of the overall combined development programs, both the current pre-clinical development program in process and the future clinical trial development strategy. Such goodwill is not deductible for tax purposes. The aggregate consideration of $18.9 million has been allocated to assets acquired and liabilities assumed based on estimated fair values at the date of merger as follows:
	Cash		$	631,478
	Goodwill			7,792,987
	In-process research and development			19,000,000
	Accrued expenses			(334,423	)
	Derivative liability			(3,476	)
	Deferred taxes			(7,463,200	)
	Convertible promissory notes (see Note 7)			(680,000	)
			$	18,943,366
	The above cash was obtained by Sonkei in a November 6, 2013 financing and thus has been classified as a financing activity in the statements of cash flows. IPR&D, an indefinite-lived asset, is included as an asset on the Company’s balance sheet until such time that: (i) a marketing approval to commercially sell the drug is received from a regulatory agency, in which case it will be amortized over its expected commercial life, or (ii) such time as the IPR&D is deemed to be impaired, in which case it will be expensed. The transaction is being treated as a stock purchase for income tax purposes and accordingly, the tax bases of Sonkei’s assets and liabilities are not adjusted for the effect of purchase accounting. A deferred tax liability of $7.6 million has been recorded for the difference in the book and tax basis of the IPR&D, multiplied by the income tax rate. The acquired net operating losses of Sonkei of approximately $5.3 million had a full valuation allowance, however, will be not limited under Internal Revenue Code Section 382 as the amount that could be utilized after limitation exceeds the amount of the net operating loss carryforward. In 2014 the Company corrected the deferred tax rate used to record a deferred tax liability at the acquisition date by recording a $0.1 million reduction to deferred tax liability with a corresponding reduction to goodwill.
	Pro Forma Results
	The unaudited financial information in the table below summarizes the combined results of operations for the Company, Sonkei and Mind-NRG on a pro forma basis as though the companies had been acquired as of January 1, 2013. The unaudited pro forma financial information for the years ended December 31, 2014 and 2013 combines the Company’s historical results for these years with the historical results for the comparable reporting periods for Sonkei and Mind-NRG. The unaudited pro forma financial information below is for informational purposes only and is not indicative of the results of operations or financial condition that would have been achieved if the acquisitions would have taken place at the beginning of each of the periods presented and should not be taken as indicative of the Company’s future results of operations or financial condition.
			Years Ended
			December 31,
			2014			2013
	Operating loss		$	(57,354,314	)	$	(5,541,476	)
	Loss per share		$	(4.51	)	$	(0.74	)

Accrued_Expenses_and_Other_Lia

Accrued Expenses and Other Liabilities	12 Months Ended
	Dec. 31, 2014
Payables And Accruals [Abstract]
Accrued Expenses and Other Liabilities	NOTE 4 — ACCRUED EXPENSES AND OTHER LIABILITIES
	Accrued expenses and other liabilities consist of the following:
			December 31, 2014		December 31, 2013
	Accrued severance		$	636,033	$	-
	Research and development costs			415,595		58,117
	Accrued bonus			327,960		—
	Primomed research funding (1)			127,209		—
	Accrued excise and franchise taxes			76,885		—
	Professional fees (2)			54,350		595,215
	Deferred rent, current			7,226		—
	Accrued payroll			—		126,910
	Consulting and other costs			—		5,031
	Vacation pay			—		5,690
	Interest payable			—		24,276
			$	1,645,258	$	815,239
	-1	Under the terms of a research agreement with Primomed, the Company received grant funds that will be used to offset
		certain costs under the MIN-301 development program.
	-2	Accounts payable and accrued professional fees at December 31, 2013 included $0.4 million incurred in
		connection with the preparation of the Company’s IPO.

Net_Loss_Per_Share_of_Common_S

Net Loss Per Share of Common Stock	12 Months Ended
	Dec. 31, 2014
Earnings Per Share [Abstract]
Net Loss Per Share of Common Stock	NOTE 5 — NET LOSS PER SHARE OF COMMON STOCK
	Diluted loss per share is the same as basic loss per share for all periods presented as the effects of potentially dilutive items were anti-dilutive given the Company’s net loss. Basic loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding. The following table sets forth the computation of basic and diluted loss per share for common stockholders:
		Year Ended December 31,
		2014			2013
	Net loss	$	(56,901,439	)	$	(3,262,005	)
	Weighted average shares of common stock outstanding		12,724,395			4,186,104
	Net loss per share of common stock – basic and diluted	$	(4.47	)	$	(0.78	)
	The following securities outstanding at December 31, 2014 and 2013 have been excluded from the calculation of weighted average shares outstanding as their effect on the calculation of loss per share is antidilutive:
		December 31,			December 31,
		2014			2013
	Non-vested stock issued (see Note 9 – Stockholders’ Equity)		—			1,275,530
	Common stock options		2,076,558			646,759
	The above table does not include the potentially dilutive securities that would be issuable under the convertible promissory notes outstanding as described in Note 7 — Convertible Promissory Notes.

License_Agreements

License Agreements	12 Months Ended
	Dec. 31, 2014
License Agreement Disclosure [Abstract]
License Agreements	NOTE 6 — LICENSE AGREEMENTS
	The Company has entered into a license agreement with Mitsubishi Tanabe Pharma Corporation (“Mitsubishi”) dated as of August 30, 2007, as amended (the “License Agreement”). Under the terms of the License Agreement, the Company acquired an exclusive license to the compound known as CYR-101 (subsequently renamed MIN-101), and other compounds with a similar structure and intended purpose and other data included within the valid claims of certain patents licensed to the Company under the License Agreement. The license is for world-wide rights, excluding certain Asian countries such as China, Japan, India and South Korea. The Company will pay a tiered royalty for net sales of product by it or any of its affiliates or sub-licensees containing the licensed compound equal to a percentage ranging from the high single digit to the low teens depending on net sales of products under the License Agreement. The initial $1.0 million licensing fee paid in 2007 was expensed as research and development expense, as was an additional payment of $0.5 million in 2008 upon the onset of a Phase IIa study. The Company made a $0.5 million extension payment in 2010 which was expensed as part of research and development expense. The Company was also required to make milestone payments upon the achievement of certain development and commercial milestones, potentially up to $57.5 million for MIN-101 and up to $59.5 million for additional products.
	In January 2014, the Company renegotiated the structure of the license for MIN-101 such that the Company is required to make milestone payments upon the achievement of one development milestone totaling $0.5 million and certain commercial milestones, which could total up to $47.5 million. In addition, in the event that the Company sells the rights to the license, the licensor will be entitled to a percentage of milestone payments in the low teens and a percentage of royalties received by the Company in the low double digits.
	In connection with the merger of Sonkei (see Note 3 — Business Combinations), the Company has a second license agreement with Mitsubishi dated September 1, 2008, as amended. Under the terms of the agreement, the Company has an exclusive license to the compound known as SON-117 (subsequently renamed MIN-117) and other data included within the valid claims of certain patents licensed to the Company under the agreement. The license is for world-wide rights other than certain countries in Asia, including China, Japan, India and South Korea. Under the agreement, the Company will pay a tiered royalty for net sales of product by it or any of its affiliates or sub-licensees containing the licensed compound ranging from the high single digits to the low teens depending on net sales of products. Through the date of the agreement, as amended, the Company was required to make payments up to $57.5 million upon the achievement of certain commercial milestones.
	In January 2014, the Company renegotiated the structure of the license for MIN-117 such that the Company is required to make certain milestone payments upon the achievement of certain commercial milestones up to $47.5 million. In addition, in the event that the Company sells the rights to the license, the licensor will be entitled to a percentage of milestone payments in the low teens and a percentage of royalties received by the Company in the low double digits. Under the terms of the amended agreement, the Company is required to meet a certain diligence obligation to initiate either a Phase IIa or Phase IIb study with the licensed compound in patients suffering major mood disorders where initiation is defined as first patient enrolled in the study by the end of April 2015. If the Company fails to achieve this milestone, the Company may elect to extend the timeline to achieve the milestone by one year increments by making an extension payment of $0.5 million. The number of extension payments which may be made is unlimited. In addition, if the Company fails to achieve this development milestone by end April 2015 or make an extension payment, the licensor may elect to terminate the agreement.
	The Company did not make any license payments under the agreements for the years ended December 31, 2014 or 2013.

Debt

Debt	12 Months Ended
	Dec. 31, 2014
Debt Disclosure [Abstract]
Debt	NOTE 7 — DEBT
	Loans Payable
	In conjunction with the Mind-NRG acquisition on February 11, 2014 (discussed further in Note 3 — Business Combinations), working capital loans were executed between Mind-NRG and several stockholders or affiliates of stockholders for a maximum drawdown of $0.6 million. The loans bear interest at 8% and are repayable at the time the Company completes an IPO or December 1, 2015. The loans may be repaid at any time and contains standard terms of default, under which the interest rate would increase to 11%.
	In April 2014, Mind-NRG repaid the working capital loans plus accrued interest, and certain stockholders and their affiliates subsequently executed new working capital loan agreements, with substantially identical terms, directly with the Company (the April Bridge Loan). The Company drew down the maximum $0.6 million available under the agreement in May 2014.
	In May 2014, the Company entered into a new loan agreement (the May Bridge Loan) with certain stockholders and their affiliates. The Third Loan Agreement provides loan facilities to the Company up to a maximum of $1.0 million. The Third Loan Agreement bears interest at 8% per annum and is repayable at the time the Company completes an IPO or on December 1, 2015. The Third Loan Agreement contains standard terms of default, under which the interest rate would increase to 11% per annum. The Third Loan Agreement provides that any amount outstanding may be repaid at any time without penalty.
	The Company drew down $1.4 million under the April and May Bridge Loan Agreements. In conjunction with the closing of the Company’s IPO on July 7, 2014, the Company repaid the outstanding principal balance under the April and May Bridge Loan agreements plus accrued interest of $11 thousand. Interest expense related to these loans during the year ended December 31, 2014 was $16 thousand and was included within interest expense (income), net.
	Convertible Promissory Notes
	On November 6, 2013, the Company issued $1.3 million 8% convertible promissory notes due June 30, 2014 to certain stockholders that are payable on demand at maturity. The notes contained certain terms of default, under which conditions the interest rate increases to 11% per annum.
	In conjunction with the merger of Sonkei on November 12, 2013, the Company assumed convertible promissory notes held by certain stockholders with a principal amount of €518,519. These notes had a stated interest rate of 8% per annum and a maturity date of June 30, 2014. In conjunction with the IPO, the Company’s 8% convertible promissory notes were converted on July 7, 2014 at the IPO price of $6.00 per share into 352,000 shares of the Company’s common stock.
	The notes issued by the Company on November 6, 2013 and the notes issued by Sonkei on November 6, 2013 and subsequently acquired by the Company on November 12, 2013 (collectively, the “Notes”) contain identical terms and may be converted into common shares of the Company under the following conditions:
	i)	Discount Purchase Option. If the Company sells shares of its capital stock in the qualified financing, as defined,
		and the convertible promissory notes have not been paid in full, then the outstanding principal balance of these
		convertible promissory notes and accrued interest thereon shall convert into the common stock sold at the first
		closing of the qualified financing at a conversion price equal to the price per share paid by the Investors for each
		share of common stock multiplied by 80%.
	ii)	Initial Public Offering. If the Company conducts an IPO of its common shares before June 30, 2014, then the
		convertible promissory notes plus accrued interest will convert at the price per share issued in the IPO.
	iii)	$3.50/€3.50 Conversion Option. Subsequent to April 30, 2014, investors may elect to convert the Notes, and
		accrued interest into common stock of the Company at a conversion price of $3.50 per common share.
	Discount Purchase Option
	The Notes contained an embedded derivative related to the discount purchase feature. The initial fair value of the derivative liability at the date of initial recognition was determined to be $9,976 using a probability-weighted valuation model applying the following assumptions: (i) discount rate of 8.0%, (ii) remaining term of approximately 7 months and (iii) the probabilities of conversion under various circumstances as at the date of measurement. The proceeds allocated to this conversion option of $9,976 were deducted from the initial fair value of the debt obligation. As of December 31, 2013, the fair value of the derivative liability was determined to be $10,093 using a probability-weighted valuation model applying the following assumptions: (i) discount rate of 8.0%, (ii) remaining term of approximately 6 months and (iii) the probabilities of conversion under various circumstances as at the date of measurement. Upon conversion of the Notes on July 7, 2014, the fair value of the derivative liability was determined to be $0 and the $10,093 decrease in the fair value of the derivative liability was included as a component of interest for the year ended December 31, 2014.
	$3.50/€3.50 Conversion Option
	The Notes contained a beneficial conversion feature. The intrinsic value of the beneficial conversion feature was calculated by measuring the difference between the effective conversion price and the fair value of the common stock at initial recognition. The Company recorded a debt discount for the intrinsic value of the beneficial conversion feature that was limited to the proceeds of the Notes received of approximately $2.0 million, with an offsetting increase to additional paid-in capital. The discount was amortized to interest expense using the effective interest method through the date of the Notes’ conversion of July 7, 2014.
	As of December 31, 2014 and 2013, the convertible promissory notes and debt discount are as follows:
			December 31, 2014		December 31, 2013
	Convertible promissory notes		$	—	$	1,973,500
	Debt discount			—		(1,937,269	)
	Foreign exchange effect on Euro denominated notes			—		22,039
			$	—	$	58,270
	For the years ended December 31, 2014 and 2013, the Company recognized interest expense of $2.0 million and $59 thousand, respectively, related to the Notes which has been included within interest expense (income), net.

CoDevelopment_and_License_Agre

Co-Development and License Agreement	12 Months Ended
	Dec. 31, 2014
Co Development And License Agreement Disclosure [Abstract]
Co-Development and License Agreement	NOTE 8 — CO-DEVELOPMENT AND LICENSE AGREEMENT
	On February 12, 2014, the Company signed a co-development and license agreement with Janssen Pharmaceutica N.V. (“Janssen”) and Janssen Research & Development, LLC (“JJDC”), subject to the completion of an IPO and the payment of a $22.0 million license fee. Under the agreement, the licensor granted the Company an exclusive license, with the right to sublicense, in the European Union, Switzerland, Liechtenstein, Iceland and Norway, referred to as the Minerva Territory, under (i) certain patent and patent applications to sell products containing any orexin 2 compound, controlled by the licensor and claimed in a licensor patent right as an active ingredient and (ii) MIN-202 for any use in humans. In addition, upon regulatory approval in the Minerva Territory (and earlier if certain default events occur), the Company will have rights to manufacture MIN-202. The Company has granted to the licensor an exclusive license, with the right to sublicense, under all patent rights and know-how controlled by the Company related to MIN-202 to sell MIN-202 outside the Minerva Territory. In consideration of the licenses granted on July 7, 2014, the Company made a license fee payment of $22.0 million, which was included as a component of research and development expense in 2014. The Company will pay a quarterly royalty percentage in the high single digits on aggregate net sales for MIN-202 products sold by the Company, its affiliates and sublicensees in the European Union. The licensor will pay a quarterly royalty percentage to the Company in the high single digits on aggregate net sales for MIN-202 products sold by the licensor outside the European Union. In accordance with the development agreement, the Company will pay 40% of MIN-202 development costs related to the joint development of any MIN-202 products. However, the Company’s share of aggregate development costs shall not exceed (i) $5.0 million for the period beginning from the effective date of the license and ending following the completion of certain Phase Ib clinical trials and animal toxicology studies, and (ii) $24.0 million for the period beginning from the effective date of the license and ending following the completion of certain Phase II clinical trials. The licensor has a right to opt out at the end of certain development milestones, with the first milestone being the completion of a single day Phase I clinical trial in patients with Major Depressive Disorder (“MDD”). Upon opt out, the licensor will not have to fund further development of MIN-202 and the Minerva Territory will be expanded to also include all of North America. The Company would then owe the licensor a reduced royalty in the mid-single digits for all sales in the Minerva Territory. The Company has the right to terminate the license following certain development milestones the first being completion of a certain Phase Ib clinical trial in patients with insomnia and certain toxicology studies in animals. If the Company terminates the license within 45 days of this milestone, the Company must pay a termination fee equal to $3.0 million. If the Company terminates the license at any time following the last development milestone involving a certain Phase IIb clinical trial, the Company will be entitled to a royalty in the mid-single digits from sales of MIN-202 by the licensor. The licensor may also terminate the agreement for the Company’s material breach or certain insolvency events, including if the Company is unable to fund its portion of the development costs.
	The Company included the $22.0 million license fee payment as a component of research and development expense since the licensed rights were not deemed to have an alternative future use. The Company accounts for the co-development and license agreement as a joint risk-sharing collaboration in accordance with ASC 808, Collaboration Arrangements. Payments between the Company and the licensor with respect to each party’s share of MIN-202 development costs that have been incurred pursuant to the joint development plan are recorded within research and development expense or general and administrative expense, as applicable, in the accompanying consolidated statements of operations due to the joint risk-sharing nature of the activities. The Company has included $1.2 million in accrued collaborative expenses as of December 31, 2014 and paid $1.2 million during the year ended December 31, 2014 related to this agreement.
	The Company entered into a common stock purchase agreement with an affiliate of the above mentioned licensor, dated as of February 12, 2014, pursuant to which, among other things, the affiliate agreed to purchase from the Company up to $26.0 million of common stock in a private placement concurrent with the closing of the IPO at a price equal to the IPO price. This investment was consummated simultaneously with the closing of an IPO in July 2014 with the purchase by the affiliate of 3,284,353 shares of common stock resulting in net proceeds to the Company of $19.7 million.

Stockholders_Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2014
Stockholders Equity Note [Abstract]
Stockholders' Equity	NOTE 9 — STOCKHOLDERS’ EQUITY
	Reverse Stock Split
	The Company’s board of directors and holders of the requisite number of outstanding shares of the Company’s common stock approved an amendment to the Company’s restated certificate of incorporation to effect a 3.5-to-1 reverse stock split of the Company’s outstanding common stock (the “reverse stock split”) that became effective on June 9, 2014 upon the filing of its Certificate of Amendment of the Restated Certificate of Incorporation with the Delaware Secretary of State. The reverse stock split did not result in an adjustment to par value. All issued and outstanding common stock, warrants for common stock, options to purchase common stock, share transactions, and related per share amounts contained in the consolidated financial statements have been retroactively adjusted to reflect this reverse stock split for all periods presented. On June 9, 2014, the Company amended its Amended and Restated Certificate of Incorporation to increase the total number of authorized shares to 225,000,000 shares, consisting of 125,000,000 shares of common stock, par value $0.0001 per share and 100,000,000 shares of preferred stock, par value $0.0001 per share.
	Initial Public Offering and Concurrent Private Placements
	On July 7, 2014, the Company closed the sale of 5,454,545 shares of its common stock at a price to the public of $6.00 per share, or an aggregate of approximately $32.7 million.  On July 29, 2014, the Company closed the sale of an over-allotment of 160,993 shares of its common stock at a price of $6.00 per share. Net proceeds to the Company from the offering and the over allotment were approximately $28.2 million, after deducting the underwriting discount and expenses of approximately $3.1 million. In addition, the Company closed the sale in a private placement of 666,666 shares of its common stock at a price of $6.00 per share, or an aggregate of approximately $4.0 million.  Net proceeds to the Company were approximately $3.7 million, after deducting the underwriting discount. JJDC purchased 3,284,353 shares of the Company’s common stock in a private placement resulting in net proceeds to the Company of approximately $19.7 million.
	Common Stock Issued for Nonrecourse Notes
	On April 26, 2012, the Company issued 821,429 shares of its common stock in exchange for a nonrecourse note of $3,058,026 (or approximately $3.71 per share, the “Original Price”). The note payable was due in a single installment on February 28, 2014, and was amended to extend the maturity date to September 30, 2014. The note bears interest at the rate of 0.19% per annum and is secured solely by the underlying stock. The stock purchase agreement contains i) a right of first refusal held by the Company, whereby if a third party buyer offers to buy the holder’s stock at a certain price, then the Company has the right to purchase the stock at that same price; and ii) a standard drag-along in case of a sale of the Company. In lieu of payment, the holder is entitled to offset amounts owed under the nonrecourse note in connection with the Company repurchasing common stock from the holder. The Company has the option (a call option) to repurchase the shares if the holder ceases to provide services to the Company or after September 30, 2014, at the Original Price. The holder has the option (a put option) to require the Company to repurchase the shares at any time at the Original Price.
	In accordance with ASC 718-10-25, the purchase of stock in exchange for a nonrecourse note effectively is the same as granting a stock option. If the value of the underlying shares falls below the note amount, the stockholder will relinquish the stock in lieu of repaying the note and would be in the same position as if he or she never purchased the stock. Further, as the shares sold subject to the nonrecourse note are considered an option for accounting purposes, the Company did not record a nonrecourse note or shares outstanding on the balance sheet. The Company also did not recognize interest income on the note as that interest is included in the exercise price of the option. The ultimate holder of the option can only benefit from the instrument if he continues to provide services to the Company through the time of a change in control, as defined. As a change in control was not deemed probable, stock-based compensation expense was not recorded for the year ended December 31, 2013.
	In December 2013, the Company issued 27,925 shares of common stock to the holder, subject to a $97,737 nonrecourse note payable by the holder. The accounting for the additional share issuance is consistent with the 821,429 shares discussed above.
	Sonkei had a similar arrangement with the consultant, whereby Sonkei issued 1,112,500 shares of its common stock in exchange for a nonrecourse note of €1,119,017 (approximately $1.5 million at December 31, 2013). The note payable was due in a single installment on April 30, 2015. The note bears interest at the rate of 0.19% per annum and is secured solely by the underlying stock. As the shares sold subject to the nonrecourse note are considered an option for accounting purposes, the Company did not record a note or shares outstanding on the balance sheet. The Company also did not recognize interest income on the note as that interest is included in the exercise price of the option. The ultimate holder of the option can only benefit from the instrument if he continues to provide services to the Company through the time of a change in control, as defined. Until a change in control is deemed probable, stock-based compensation expense will not be recorded until a change in control occurs at the then fair value of the option. The Company assumed this agreement upon the merger with Sonkei, and the Sonkei shares were converted into the Company’s common shares in accordance with the terms of the merger agreement (see Note 3 — Business Combinations). On March 31, 2014, the issuer of the $4.7 million nonrecourse notes, which includes accrued interest, remitted to the Company 348,926 shares of common stock with a fair value of $13.51 per share in full settlement of the outstanding note due in a cashless transaction. Additionally, the Company further modified the awards by cancelling the put option and adding a term whereby upon an IPO the award will vest. The remittance of the shares in exchange for settling the outstanding note, the cancellation of the put option, and the addition of the IPO performance condition, represents a modification of the original terms of the stock options. The effect of these changes is that the Company has modified the awards and has converted approximately 1.3 million stock options with an exercise price of $4.7 million to 926,604 shares of non-vested stock (with no exercise price). The non-vested stock remained subject to the above mentioned vesting conditions of a change in control and IPO, which are not deemed probable until they occur. As described in the preceding sentence, the effect of the modification was to replace stock options that were improbable of vesting with non-vested stock that is improbable of vesting and accordingly, the Company did not recognize stock-based compensation expense for the non-vested stock at the time that the vesting conditions are deemed probable of occurrence.  The following is a summary of common shares issued in exchange for nonrecourse notes for the years December 31, 2014 and 2013:
		Common Shares
	Outstanding December 31, 2012		821,429
	Assumed in Sonkei merger		426,176
	Issued		27,925
	Outstanding December 31, 2013		1,275,530
	Repurchased		-348,926
	Shares vested June 30, 2014		926,604
	The 926,604 shares of non-vested common stock held by the consultant became probable of vesting upon the effectiveness of the Company’s IPO registration statement on June 30, 2014, resulting in a charge for stock-based compensation of approximately $10.5 million, representing the 926,604 shares multiplied by the fair value per share on May 1, 2014, the date the consultant became an employee, less previous compensation expense recorded.
	Common Stock Issued to Consultant
	On December 20, 2013, the Company sold 24,516 shares of common stock to the consultant for an aggregate purchase price of $8.58. The Company recognized the fair value of the shares less the par value as an administrative expense of $232,534.

Stock_Option_Plan

Stock Option Plan	12 Months Ended
	Dec. 31, 2014
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock Option Plan	NOTE 10 — STOCK OPTION PLAN
	The Company adopted the 2013 Equity Incentive Plan (“Plan”) in December 2013, which provides for the issuance of options, stock appreciation rights, stock awards and stock units. On April 30, 2014, the Company increased the number of shares of common stock reserved for issuance over the term of the Plan to 3,543,754 shares. The exercise price per share shall not be less than the fair value of the Company’s underlying common stock on the grant date and no option may have a term in excess of ten years. Stock option activity under the Plan for the years ended December 31, 2014 and 2013 is as follows:
					Weighted-Average
		Stock Options			Exercise Price
	Outstanding January 1, 2013		—			—
	Granted		646,759		$	9.49
	Outstanding December 31, 2013		646,759		$	9.49
	Granted		1,975,151		$	6.05
	Forfeited		(545,352	)	$	7.89
	Outstanding December 31, 2014		2,076,558		$	6.64
	Exercisable December 31, 2014		1,286,890		$	6.91
	The fair value of each stock option to purchase common stock of the Company granted on December 20, 2013 was estimated by management using the Black-Scholes option pricing model applying the following assumptions: (i) expected term of 5.8 to 10 years, (ii) risk free interest rate of 1.9 to 2.9%, (iii) volatility of 102 to 107%, (iv) no dividend yield and (v) a grant date fair value of common stock of $9.49 per share. The Company recognized stock-based compensation expense for the year ended December 31, 2014 and 2013 related to these options of $2.1 million and $0.4 million, respectively, which is included in general and administrative expense.
	The table above includes stock options granted on December 20, 2013 to purchase an aggregate of 20,089 shares of the Company’s common stock which became fully vested and exercisable on June 30, 2014, the effective date of the Company’s IPO registration statement.  The Company recognized stock-based compensation expense for the year ended December 31, 2014 related to these options of $0.2 million, which is included in general and administrative expense.
	The Company entered into two employment agreements effective May 1, 2014. In accordance with the employment agreements, on June 30, 2014, the Company granted 539,116 fully vested stock options to purchase shares of the Company’s common shares at an exercise price of $6.00 per share and recognized stock based compensation expense of approximately $2.7 million related to these grants on the grant date. The fair value of each such option was estimated by management using the Black Scholes option pricing model applying the following assumptions: (i) expected term of 6.25 years, (ii) risk free interest rate of 1.9%, (iii) volatility of 113%, (iv) no dividend yield and (v) a grant date fair value of common stock of $6.00 per share.
	Under the terms of three employment agreements, the Company issued 955,932 stock options upon the effective date of the Company's IPO registration statement, which vest over a four-year period beginning from November 12, 2013, the date of the Sonkei Merger.  The Company recognized stock-based compensation expense related to these options of approximately $1.9 million for the year ended December 31, 2014.  The fair value of each such option was estimated by management using the Black Scholes option pricing model applying the following assumptions: (i) expected term of 6.25 years, (ii) risk free interest rate of 1.9%, (iii) volatility of 113%, (iv) no dividend yield and (v) a grant date fair value of common stock of $6.00 per share.
	An additional 480,103 options were granted to employees and directors at and following the IPO of which 352,590 options vest over a four year period and 127,513 options vest over a three year period beginning with the date each recipient began providing service. The Company recognized stock-based compensation expense related to these options of approximately $0.5 million for the year ended December 31, 2014.  The fair value of each of these options to purchase common stock of the Company granted was estimated by management using the Black Scholes option pricing model applying the following assumptions: (i) expected term of 6-6.25 years, (ii) risk free interest rate of 1.9%, (iii) volatility of 113%, (iv) no dividend yield.
	The weighted average grant-date fair value of stock options outstanding on December 31, 2014 was $5.63 per share. Total unrecognized compensation costs related to non-vested awards at December 31, 2014 was approximately $4.0 million and is expected to be recognized within future operating results over a period of 3.75 years. At December 31, 2014, the weighted average contractual term of the options outstanding is approximately 9.4 years. The intrinsic value of outstanding stock options at December 31, 2014 was $37 thousand.
	The expected term of the employee-related options was estimated using the “simplified” method as defined by the Securities and Exchange Commission’s Staff Accounting Bulletin No. 107, Share-Based Payment. The volatility assumption was determined by examining the historical volatilities for industry peer companies, as the Company did not have any trading history for its common stock. The risk-free interest rate assumption is based on the U.S. Treasury instruments whose term was consistent with the expected term of the options. The dividend assumption is based on the Company’s history and expectation of dividend payouts. The Company has never paid dividends on its common stock and does not anticipate paying dividends on its common stock in the foreseeable future. Accordingly, the Company has assumed no dividend yield for purposes of estimating the fair value of the options.

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Income Taxes	NOTE 11 — INCOME TAXES
	Net deferred tax assets (liabilities) as of December 31, 2014 and 2013 consist of the following:
		2014			2013
	Deferred tax assets:
	Net operating loss carryforwards	$	11,384,959		$	5,886,683
	Research and development tax credits		145,115			141,231
	Capitalized research and development costs		3,067,414			—
	Stock-based compensation		2,961,324			88,368
	Deferred start-up and license costs		11,991,001			2,705,248
	Net deferred tax assets		29,549,813			8,821,530
	Valuation allowance		(29,549,813	)		(8,821,530	)
	Net deferred tax assets	$	—		$	—
	Deferred tax liabilities:
	In-process research and development		(13,433,760	)		(7,588,600	)
	Net deferred tax liabilities	$	(13,433,760	)	$	(7,588,600	)
	A reconciliation between the Company’s effective tax rate and the federal statutory rate for the years ended December 31, 2014 and 2013 are as follows:
		2014			2013
	Federal statutory rate		(34.00	%)		(34.00	%)
	Permanent differences		4.27	%		(2.49	%)
	State income taxes		(4.62	%)		(5.94	%)
	Valuation allowance		34.35	%		42.43	%
	Effective tax rate		0	%		0	%
	In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of the deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income, and tax planning strategies in making this assessment. Based upon the level of historical losses and the uncertainty of future taxable income over the periods which the Company will realize the benefits of its net deferred tax assets, management believes it is more likely than not that the Company will not realize the benefits on the balance of its net deferred tax asset and, accordingly, the Company has established a full valuation allowance on its net deferred tax assets. The valuation allowance increased by approximately $20.7 million and $3.3 million during the years ended December 31, 2014 and 2013, respectively.
	As of December 31, 2014, the Company had approximately $26.4 million of Federal net operating losses that will begin to expire in 2027. As of December 31, 2014, the Company's wholly owned subsidiary had approximately $4.9 million of operating losses in Switzerland that will begin to expire in 2018. As of December 31, 2014, the Company had approximately $10.4 million of New Jersey and $11.0 million of Massachusetts operating losses that will begin to expire in 2015 and 2024, respectively. As of December 31, 2014, the Company had approximately $0.1 million of federal research and development credits that will begin to expire in 2028. The Internal Revenue Code (“IRC”) limits the amounts of net operating loss carryforwards that a company may use in any one year in the event of certain cumulative changes in ownership over a three-year period as described in Section 382 of the IRC. The Company has not performed a detailed analysis to determine whether an ownership change has occurred as of December 31, 2014.
	Deferred tax liabilities related to indefinite-lived assets typically are not used as a source of income to support realization of deferred tax assets in jurisdictions where tax attributes expire (e.g., jurisdictions where net operating loss carryforwards expire) unless the deferred tax liability is expected to reverse prior to the expiration date of the tax attribute. Therefore, the net operating losses of Sonkei cannot be used to offset the deferred tax liability resulting from the IPR&D due to the fact that the IPR&D currently has an indefinite life while the NOLs have a maximum life of 20 years.

Commitments

Commitments	12 Months Ended
	Dec. 31, 2014
Commitments And Contingencies Disclosure [Abstract]
Commitments	NOTE 12 — COMMITMENTS
	In September 2014, the Company entered into a lease agreement for 4,043 square feet of office space in Waltham, MA. The term of the lease is approximately 2 years, and the Company is required to make monthly rental payments commencing December 2014. Estimated annual rent payable under this operating lease is approximately $0.1 million per year in each of the two years.

Related_Party_Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2014
Related Party Transactions [Abstract]
Related Party Transactions	NOTE 13 — RELATED PARTY TRANSACTIONS
	The Company reimbursed certain expenses paid by its investors incurred on behalf of the Company. For the years ended December 31, 2014 and 2013, these reimbursements were $268,990 and $111,351, respectively.
	An investor provided accounting and other services to the Company for $60,000 per year. An additional $5,000 was charged for maintaining the Sonkei records in 2013. For the years ended December 31, 2014 and 2013, the total expense recognized in operating results in connection with services provided was $35,000 and $65,000, respectively.
	For the years ended December 31, 2014 and 2013, the Company retained the services of certain consultants who were also stockholders of the Company (see Note 9 – Stockholders’ Equity). The total expense recognized by the Company in connection with these consulting services was $247,400 and $538,996 for the years ended December 31, 2014 and 2013, respectively.
	The Company’s convertible promissory notes were held by certain stockholders. Accrued interest payable listed in Note 4 as of December 31, 2013 relates to these convertible promissory notes. Also refer to Note 8 – Co-Development and License agreement and Note 9 – Stockholder’s Equity for additional related party transactions.

Quarterly_Results_Unaudited

Quarterly Results (Unaudited)	12 Months Ended
	Dec. 31, 2014
Quarterly Financial Information Disclosure [Abstract]
Quarterly Results	NOTE 14 — QUARTERLY RESULTS (Unaudited)
		Three Months Ended
		31-Mar-14			30-Jun-14			30-Sep-14			31-Dec-14
		(in thousands, except per share data)
	Total revenues	$	-		$	-		$	-		$	-
	Operating loss		(2,623	)		(17,650	)		(27,151	)		(7,446	)
	Net loss		(2,938	)		(19,366	)		(27,155	)		(7,442	)
	Loss per share, basic and diluted	$	(0.43	)	$	(2.55	)	$	(1.53	)	$	(0.40	)
		Three Months Ended
		31-Mar-13			30-Jun-13			30-Sep-13			31-Dec-13
		(in thousands, except per share data)
	Total revenues	$	-		$	-		$	-		$	-
	Operating loss		(271	)		(379	)		(482	)		(2,043	)
	Net loss		(271	)		(376	)		(488	)		(2,127	)
	Loss per share, basic and diluted	$	(0.08	)	$	(0.10	)	$	(0.12	)	$	(0.41	)

Subsequent_Events

Subsequent Events	12 Months Ended
	Dec. 31, 2014
Subsequent Events [Abstract]
Subsequent Events	NOTE 15 — SUBSEQUENT EVENTS
	The Company evaluated subsequent events for financial reporting purposes through the date which the financial statements were issued to determine whether any events occurred that required disclosure in the accompanying consolidated financial statements.
	Stock Option Plan
	On January 1, 2015, in accordance with the terms of the Company’s 2013 Equity Incentive Plan, the total shares authorized for issuance under the plan increased by 737,579 to 4,281,333.  This increase represents 4% of the total shares outstanding calculated as of the end of the most recent fiscal year.  On January 2, 2015, the Company granted 10,000 stock options to purchase common shares to a newly hired employee at an exercise price of $6.11 and on February 2, 2015 granted a total of 15,000 stock options to purchase common shares to two members of the Board of Directors at an exercise price of $4.34.
	Loan and Security Agreement
	On January 16, 2015, the Company entered into a Loan and Security Agreement (the “Loan Agreement”) with Oxford Finance LLC (“Oxford”) and Silicon Valley Bank (“SVB” and, together with Oxford, the “Lenders”), providing for term loans to the Company in an aggregate principal amount of up to $15 million, in two tranches.
	The Company drew down the initial term loans in the aggregate principal amount of $10 million (the “Term A Loans”) on January 16, 2015. The Term A Loans bear interest at a fixed rate of 7.05% per annum. On or prior to March 31, 2016, the Company may borrow additional term loans (the “Term B Loans” and, together with the Term A Loans, the “Term Loans”) in the aggregate principal amount up to $5 million, subject to the satisfaction of certain borrowing conditions, including its achievement of primary endpoints on its Phase IIa trials for its MIN-117 and MIN-202 programs. The Term B Loans will bear interest at a fixed rate per annum of the greater of (i) 7.05% or (ii) the sum of (a) the prime rate reported in The Wall Street Journal three (3) business days prior to the funding date of the Term B Loans, plus (b) 3.80%.
	The Company paid a facility fee of $75,000 for access to the Term Loans and will be required to pay a final payment of 4.45% (or, if the interest-only period is extended as described below, 5.10%) of the total amount borrowed. Through February 1, 2016, the Company is obligated only to make monthly interest payments on the outstanding principal balance on the Term A Loans, followed by thirty (30) months of equal principal and interest payments. If the Company raises at least $30,000,000 in capital (including at least $20,000,000 from the sale of equity securities) and completes the first dosing of its Phase I/II clinical trial for MIN-117 prior to December 31, 2015, the interest-only period will be extended an additional six (6) months and the repayment period will be reduced by six (6) months. The Term Loans mature on August 1, 2018. The Company may prepay all, but not less than all, of the loaned amount upon thirty (30) days’ advance notice to the Lenders, provided that the Company will be obligated to pay a prepayment fee equal to (i) 3% of the outstanding balance, if the loan is prepaid within twenty-four (24) months of the funding date, (ii), 2% of the outstanding balance, if the loan is prepaid between twenty-four (24) and thirty-six (36) months of the funding date and (iii) 1% of the outstanding balance, if the loan is prepaid thereafter (each, a “Prepayment Fee”).
	While any amounts are outstanding under the loan agreement, the Company is subject to a number of affirmative and restrictive covenants, including covenants regarding delivery of financial statements, maintenance of inventory, payment of taxes, maintenance of insurance, dispositions of property, business combinations or acquisitions, incurrence of additional indebtedness and transactions with affiliates, among other customary covenants. The Company is also restricted from paying dividends or making other distributions or payments on its capital stock, subject to limited exceptions.
	The Company’s obligations under the Loan Agreement are secured by a first priority security interest in substantially all of its assets, other than its intellectual property. The Company has also agreed not to pledge or otherwise encumber its intellectual property assets, except that it may grant certain exclusive and non-exclusive licenses of its intellectual property as set forth in the Loan Agreement. In addition, the Company pledged all of its equity interests in Minerva Neurosciences Securities Corporation and 65% of its equity interests in Mind-NRG, SA as security for its obligations under the Loan Agreement.
	Upon the occurrence of certain events, including but not limited to the Company’s failure to satisfy its payment obligations under the Loan Agreement, the breach of certain of its other covenants under the Loan Agreement, or the occurrence of a material adverse change, the Lenders will have the right, among other remedies, to declare all principal and interest immediately due and payable, and will have the right to receive the final payment fee and, if the payment of principal and interest is due prior to maturity, the applicable Prepayment Fee.
	Under the Loan Agreement, the Company agreed to issue the Lenders warrants (the “Warrants”) to purchase shares of its common stock, $0.0001 par value per share (“Common Stock”), upon its draw of each tranche of the Term Loans. The aggregate number of shares of Common Stock issuable upon exercise of the Warrants is equal to 2.25% of the amount drawn of such tranche, divided by the average closing price per share of Common Stock reported on the NASDAQ Global Market for the ten (10) consecutive trading days prior to the applicable draw.
	On January 16, 2015, upon the draw of the Term A Loans, the Company issued the Lenders Warrants to purchase 40,790 shares of Common Stock at a per share exercise price of $5.516. The Warrants are immediately exercisable upon issuance, and other than in connection with certain mergers or acquisitions, will expire on the ten-year anniversary of the date of issuance.
	Private Placement
	On March 18, 2015, pursuant to a securities purchase agreement with certain accredited investors dated March 13, 2015, the Company sold in a private placement 6,281,661 shares of the Company’s common stock at a price per share of $4.81 and warrants to purchase up to an aggregate of 6,281,661 shares of common stock at a purchase price of $0.125 per warrant share, with an initial exercise price of $5.772 per share.  The Company received net proceeds of approximately $28.8 million, after deducting placement agent fees.  The warrants will expire on March 18, 2017, two years after the date on which they were initially issued.
	In connection with the private placement, the Company also entered into a Registration Rights Agreement, dated March 13, 2015 (the “Registration Rights Agreement”) with certain accredited investors. Pursuant to the terms of the Registration Rights Agreement, the Company is obligated to prepare and file with the SEC a registration statement to register for resale the shares of its common stock issued in the private placement and the shares of its common stock issuable upon exercise of the warrants on or prior to May 2, 2015.  If registration statements are not filed timely or are not maintained effective, the Company could be subject to penalties of up to 10% of proceeds received in the private placement.

Significant_Accounting_Policie1

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Basis of Presentation	Basis of presentation
	The financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”), and include all adjustments necessary for the fair presentation of the Company’s financial position for the periods presented. From its inception, the Company has devoted substantially all of its efforts to business planning, engaging regulatory, manufacturing and other technical consultants, planning and executing clinical trials and raising capital.
Consolidation	Consolidation
	The accompanying consolidated financial statements include the results of the Company and its wholly-owned subsidiaries, Mind-NRG SA and Minerva Neurosciences Securities Corporation.  Intercompany transactions have been eliminated.
Significant Risks and Uncertainties	Significant risks and uncertainties
	The Company’s operations are subject to a number of factors that can affect its operating results and financial condition. Such factors include, but are not limited to: the results of clinical testing and trial activities of the Company’s products, the Company’s ability to obtain regulatory approval to market its products, competition from products manufactured and sold or being developed by other companies, the price of, and demand for, Company products, the Company’s ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products, and the Company’s ability to raise capital.
	The Company currently has no commercially approved products and there can be no assurance that the Company’s research and development will be successfully commercialized. Developing and commercializing a product requires significant time and capital and is subject to regulatory review and approval as well as competition from other biotechnology and pharmaceutical companies. The Company operates in an environment of rapid change and is dependent upon the continued services of its employees and consultants and obtaining and protecting intellectual property.
Use of Estimates	Use of estimates
	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.
	Prior to the Company’s IPO, the Company utilized significant estimates and assumptions in determining the fair value of its common stock. The board of directors has determined the estimated fair value of the Company’s common stock based on a number of objective and subjective factors, including external market conditions affecting the biotechnology industry sector, discounted cash flows and the likelihood of achieving a liquidity event, such as an IPO of common stock or a sale of the Company.
Research and Development Costs	Research and development costs
	Costs incurred in connection with research and development activities are expensed as incurred. These costs include licensing fees to use certain technology in the Company’s research and development projects as well as fees paid to consultants and various entities that perform certain research and testing on behalf of the Company. The Company determines expenses related to clinical studies based on estimates of the services received and efforts expended pursuant to contracts with multiple research institutions and contract research organizations that conduct and manage clinical studies on its behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, the accrual is adjusted accordingly. The expenses for some trials may be recognized on a straight-line basis if the expected costs are expected to be incurred ratably during the period. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the consolidated financial statements as prepaid or accrued expenses.
	In July 2014, the Company paid a $22.0 million license fee, which has been included as a component of research and development expense since the licensed rights were not deemed to have an alternative future use. The Company accounts for the co-development and license agreement pursuant to which the license fee was paid as a joint risk-sharing collaboration in accordance with ASC 808, Collaboration Arrangements. Costs between the Company and the licensor with respect to each party’s share of development costs that have been incurred pursuant to the joint development plan are recorded within research and development expense or general and administrative expense, as applicable, in the accompanying consolidated financial statements due to the joint risk-sharing nature of the activities. The Company has included $1.2 million in accrued expenses as of December 31, 2014 related to this agreement.
	In-process research and development (“IPR&D”) assets represent capitalized incomplete research projects that the Company acquired through business combinations. Such assets are initially measured at their acquisition date fair values. The fair value of the research projects is recorded as intangible assets on the balance sheet, rather than expensed, regardless of whether these assets have an alternative future use.
	The amounts capitalized are being accounted for as indefinite-lived intangible assets, subject to impairment testing, until completion or abandonment of research and development efforts associated with the project. An IPR&D asset is considered abandoned when it ceases to be used (that is, research and development efforts associated with the asset have ceased, and there are no plans to sell or license the asset or derive defensive value from the asset). At that point, the asset is considered to be disposed of and is written off. Upon successful completion of each project, the Company will make a determination about the then remaining useful life of the intangible asset and begin amortization. The Company tests its indefinite-lived intangibles, IPR&D assets, for impairment annually on November 30 and more frequently if events or changes in circumstances indicate that it is more likely than not that the asset is impaired. When testing indefinite-lived intangibles for impairment, the Company may assess qualitative factors for its indefinite-lived intangibles to determine whether it is more likely than not (that is, a likelihood of more than 50 percent) that the asset is impaired. Alternatively, the Company may bypass this qualitative assessment for some or all of its indefinite-lived intangibles and perform the quantitative impairment test that compares the fair value of the indefinite- lived intangible asset with the asset’s carrying amount. There was no impairment of IPR&D for the years ended December 31, 2014 and 2013.
Stock-Based Compensation	Stock-based compensation
	The Company recognizes compensation cost relating to stock-based payment transactions in operating results using a fair-value measurement method, in accordance with ASC Topic 718 Compensation-Stock Compensation. ASC-718 requires all stock-based payments to employees, including grants of employee stock options, to be recognized in operating results as compensation expense based on fair value over the requisite service period of the awards. The Company determines the fair value of stock-based awards using the Black-Scholes option-pricing model which uses both historical and current market data to estimate fair value. The method incorporates various assumptions such as the risk-free interest rate, expected volatility, expected dividend yield, expected forfeiture rate and expected life of the options.
	Grants to non-employees are accounted for in accordance with ASC Topic 505-50 Equity — Based Payments to Non-Employees. The date of expense recognition is the earlier of the date at which a commitment for performance by the counterparty to earn the equity instrument is reached or the date at which the counterparty’s performance is complete. The Company determines the fair value of stock-based awards granted to non-employees similar to the way fair value of awards are determined for employees except that certain assumptions used in the Black-Scholes option-pricing model, such as expected life of the option, may be different and the fair value of each unvested award is adjusted at the end of each period for any change in fair value from the previous valuation until the award vests.
	Prior to the IPO, the Company utilized various valuation methodologies in accordance with the framework of the 2013 American Institute of Certified Public Accountants Technical Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation, to estimate the fair value of its common stock. The methodologies included a probability-weighted expected return methodology that determined an estimated value under an IPO scenario and a sale scenario based upon an assessment of the probability of occurrence of each scenario. Each valuation methodology includes estimates and assumptions that require the Company’s judgment. These estimates include assumptions regarding future performance, including the successful completion of preclinical studies and clinical trials and the time to complete an IPO or sale.
Foreign Currency Transactions	Foreign currency transactions
	The Company’s functional currency is the US dollar. The Company pays certain vendor invoices in the respective foreign currency. The Company records an expense in US dollars at the time the liability is incurred. Changes in the applicable foreign currency rate between the date an expense is recorded and the payment date is recorded as a foreign currency gain or loss.
Loss Per Share	Loss per share
	Basic loss per share excludes dilution and is computed by dividing net loss by the weighted-average number of shares of common stock outstanding for the period. Diluted loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that shared in the earnings of the entity.
Income Taxes	Income taxes
	The Company utilizes the liability method of accounting for income taxes as required by FASB ASC Topic 740 Income Taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax reporting bases of assets and liabilities and are measured using enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. Uncertain tax positions are evaluated in accordance with this topic and if appropriate, the amount of unrecognized tax benefits are recorded within deferred tax assets. Deferred tax assets are evaluated for realization based on a more-likely-than-not criterion in determining if a valuation allowance should be provided. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized.
	ASC Topic 740 also clarifies the accounting for uncertainty in income taxes recognized in the financial statements. The interpretation prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken, or expected to be taken, in a tax return. ASC Topic 740 provides guidance on the recognition of interest and penalties related to income taxes. There was no interest or penalties related to income taxes for the years ended December 31, 2014 and 2013. The Company has elected to treat interest and penalties, to the extent they arise, as a component of income taxes. Income tax years beginning in 2011 for federal and state purposes are generally subject to examination by taxing authorities, although net operating losses from all prior years are subject to examinations and adjustments for at least three years following the year in which the tax attributes are utilized.
Concentration of Credit Risk	Concentration of credit risk
	Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash and cash equivalents. The Company maintains its cash and cash equivalent balances in the form of business checking accounts and money market accounts, the balances of which, at times, may exceed federally insured limits. Exposure to credit risk is reduced by placing such deposits with major financial institutions and monitoring their credit ratings.
Cash and Cash Equivalents	Cash and cash equivalents
	The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents.
Equipment	Equipment
	Equipment is stated at cost less accumulated depreciation. Equipment is depreciated on the straight-line basis over their estimated useful lives of three years. Expenditures for maintenance and repairs are charged to expense as incurred.
Deferred Public Offering Costs	Deferred public offering costs
	Deferred public offering costs included certain legal, accounting and other costs directly attributable to the Company’s proposed public offering of common stock. Upon completion of the initial public offering in 2014, these amounts were offset against the proceeds of the offering.
Long-Lived Assets	Long-lived assets
	The Company reviews the recoverability of all long-lived assets, including the related useful lives, whenever events or changes in circumstances indicate that the carrying amount of a long-lived asset might not be recoverable. If required, the Company compares the estimated undiscounted future net cash flows to the related asset’s carrying value to determine whether there has been an impairment. If an asset is considered impaired, the asset is written down to fair value, which is based either on discounted cash flows or appraised values in the period the impairment becomes known. The Company believes that all long-lived assets are recoverable, and no impairment was deemed necessary at December 31, 2014 and 2013.
Business Combinations	Business Combinations
	For business combinations, the Company utilizes the acquisition method of accounting in accordance with ASC Topic 805, Business Combinations. These standards require that the total cost of an acquisition be allocated to the tangible and intangible assets acquired and liabilities assumed based their respective fair values at the date of acquisition. The allocation of the purchase price is dependent upon certain valuations and other studies. Acquisition costs are expensed as incurred. The Company recognizes separately from goodwill the fair value of assets acquired and the liabilities assumed. Goodwill as of the acquisition date is measured as the excess of consideration transferred and the acquisition date fair values of the assets acquired and liabilities assumed. While the Company uses its best estimates and assumptions as a part of the purchase price allocation process to accurately value assets acquired and liabilities assumed at the acquisition date, the Company’s estimates are subject to refinement. As a result, during the measurement period, which may be up to one year from the acquisition date, the Company may retroactively record adjustments to the fair value of the assets acquired and liabilities assumed, with the corresponding offset to goodwill. Upon the conclusion of the measurement period or final determination of the fair value of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded to the Company’s consolidated statements of operations.
Goodwill	Goodwill
	The Company tests its goodwill for impairment annually, or whenever events or changes in circumstances indicate an impairment may have occurred, by comparing its reporting unit’s carrying value to its implied fair value. Impairment may result from, among other things, deterioration in the performance of the acquired business, adverse market conditions, adverse changes in applicable laws or regulations and a variety of other circumstances. If the Company determines that an impairment has occurred, it is required to record a write-down of the carrying value and charge the impairment as an operating expense in the period the determination is made. In evaluating the recoverability of the carrying value of goodwill, the Company must make assumptions regarding estimated future cash flows and other factors to determine the fair value of the acquired assets. Changes in strategy or market conditions could significantly impact those judgments in the future and require an adjustment to the recorded balances. The Company tested its goodwill for impairment as of November 30. There was no impairment of goodwill for the years ended December 31, 2014 and 2013.
Fair Value of Financial Instruments	Fair value of financial instruments
	The Company provides disclosure of financial assets and financial liabilities that are carried at fair value based on the price that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value measurements may be classified based on the amount of subjectivity associated with the inputs to fair valuation of these assets and liabilities using the following three levels:
	Level 1 — Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.
	Level 2 — Inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (i.e., interest rates, yield curves, etc.) and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs).
	Level 3 — Unobservable inputs that reflect the Company’s estimates of the assumptions that market participants would use in pricing the asset or liability. The Company develops these inputs based on the best information available, including its own data.
	The following table presents information about the Company’s derivative liability as of December 31, 2013 measured at fair value on a recurring basis and indicates the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value:
		December 31, 2013
	In thousands	Total		Level 1		Level 2		Level 3
	Derivative liability:	$	10	$	—	$	—	$	10
	The derivative liability ceased upon the conversion of the convertible promissory notes into common stock in July 2014. The carrying amounts of cash, cash equivalents, accounts payable and accrued liabilities approximate fair value because of their short-term nature.
Convertible Promissory Notes	Convertible Promissory Notes
	The Company’s convertible promissory notes at December 31, 2013 consisted of (i) $1.3 million face value convertible promissory notes, plus accrued interest of $15,671 and (ii) €518,519 face value convertible promissory notes, plus accrued interest of $8,605. The Euro denominated notes were acquired in conjunction with the merger with Sonkei (discussed further in Note 3 — Business Combinations), and recorded at their fair value of $680,000 on the date of the merger. At December 31, 2013, the fair market value of the convertible promissory notes was approximately $2.0 million. The carrying value of the convertible promissory notes at December 31, 2013 was $58,270, as a result of the beneficial conversion feature recorded at initial recognition as a debt discount.
	Discount Purchase Option
	The Company’s 8% convertible promissory notes contained an embedded derivative related to the conversion option containing a discount purchase feature in a qualified financing, as defined. The derivative is carried at fair value and is classified as Level 3 in the fair value hierarchy due to the use of significant unobservable inputs. The initial fair value of the derivative liability at the date of issuance in November 2013 was determined to be $9,976 using a probability-weighted valuation model applying the following assumptions: (i) discount rate of 8.0%, (ii) remaining term of approximately 7 months and (iii) the probabilities of conversion under various circumstances as at the date of measurement.
	As of December 31, 2013, the fair value of the derivative liability was determined to be $10,093 using a probability-weighted valuation model applying the following assumptions: (i) discount rate of 8.0%, (ii) remaining term of approximately 6 months and (iii) the probabilities of conversion under various circumstances as at the date of measurement. The $117 increase in the fair value of the derivative liability was recognized in interest expense as a loss on change in fair value of derivative liability for the year ended December 31, 2013.
	$3.50/€3.50 Conversion Option
	The Company’s 8% convertible promissory notes contained a beneficial conversion feature. The intrinsic value of the beneficial conversion feature was calculated by measuring the difference between the effective conversion price and the fair value of common stock at initial recognition. The Company recorded a debt discount for the fair value of the derivative, which was limited to the proceeds received of approximately $2.0 million, with an offsetting increase to additional paid-in capital. The beneficial conversion charge has been included in the balance sheet at December 31, 2013 as a discount to the related convertible promissory notes. The discount was accreted as non-cash interest expense over the expected term of the debt (June 30, 2014) using the effective interest method, which totaled $2.0 million and $36,231 for the years ended December 31, 2014 and 2013, respectively.
Segment Information	Segment information
	Operating segments are defined as components of an enterprise (business activity from which it earns revenue and incurs expenses) about which discrete financial information is available and regularly reviewed by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company’s chief decision maker, who is the Chief Executive Officer, reviews operating results to make decisions about allocating resources and assessing performance for the entire Company. The Company views its operations and manages its business as one operating segment.
Recent Accounting Pronouncements	Recent Accounting Pronouncements
	In June 2014 the Financial Accounting Standards Board (FASB) issued Accounting Standards Update 2014-10 Development Stage Entities (Topic 915) Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities.  The amendments in this Update 2014-10 removed the definition of a development stage entity from the Master Glossary of the Accounting Standards Codification, thereby removing the financial reporting distinction between development stage entities and other reporting entities from U.S. GAAP. In addition, the amendments eliminated the requirements for development stage entities to (1) present inception-to-date information in the statements of income, cash flows, and shareholder equity, (2) label the financial statements as those of a development stage entity, (3) disclose a description of the development stage activities in which the entity is engaged and (4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage. The Company adopted this pronouncement in 2014 and has eliminated the above mentioned disclosures.
	From time to time, new accounting pronouncements are issued by FASB and are adopted by the Company as of the specified effective date. The Company believes that the impact of other recently issued but not yet adopted accounting pronouncements will not have a material impact on the consolidated financial position, consolidated results of operations, and consolidated cash flows, or do not apply to the Company.

Significant_Accounting_Policie2

Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Fair Value of Liabilities Measured on Recurring Basis and Determined by Valuation Techniques	The following table presents information about the Company’s derivative liability as of December 31, 2013 measured at fair value on a recurring basis and indicates the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value:
		December 31, 2013
	In thousands	Total		Level 1		Level 2		Level 3
	Derivative liability:	$	10	$	—	$	—	$	10

Business_Combinations_Tables

Business Combinations (Tables)	12 Months Ended
	Dec. 31, 2014
Pro Forma Results	The unaudited pro forma financial information below is for informational purposes only and is not indicative of the results of operations or financial condition that would have been achieved if the acquisitions would have taken place at the beginning of each of the periods presented and should not be taken as indicative of the Company’s future results of operations or financial condition.
		Years Ended
		December 31,
		2014			2013
	Operating loss	$	(57,354,314	)	$	(5,541,476	)
	Loss per share	$	(4.51	)	$	(0.74	)
Mind-NRG
Aggregate Consideration Allocated to Assets Acquired and Liabilities Assumed	The aggregate consideration of $16.5 million has been allocated to assets acquired and liabilities assumed based on estimated fair values at December 31, 2013 as follows:
	Cash	$	1,167,869
	Other assets		71,130
	Goodwill		7,076,412
	In-process research and development		15,200,000
	Deferred tax liability		(5,970,560	)
	Accrued expenses		(321,417	)
	ProteoSys milestone payable		(681,600	)
		$	16,541,834
Sonkei
Aggregate Consideration Allocated to Assets Acquired and Liabilities Assumed	The aggregate consideration of $18.9 million has been allocated to assets acquired and liabilities assumed based on estimated fair values at the date of merger as follows:
	Cash	$	631,478
	Goodwill		7,792,987
	In-process research and development		19,000,000
	Accrued expenses		(334,423	)
	Derivative liability		(3,476	)
	Deferred taxes		(7,463,200	)
	Convertible promissory notes (see Note 7)		(680,000	)
		$	18,943,366

Accrued_Expenses_and_Other_Lia1

Accrued Expenses and Other Liabilities (Tables)	12 Months Ended
	Dec. 31, 2014
Payables And Accruals [Abstract]
Schedule of Accrued Expenses and Other Liabilities	Accrued expenses and other liabilities consist of the following:
			December 31, 2014		December 31, 2013
	Accrued severance		$	636,033	$	-
	Research and development costs			415,595		58,117
	Accrued bonus			327,960		—
	Primomed research funding (1)			127,209		—
	Accrued excise and franchise taxes			76,885		—
	Professional fees (2)			54,350		595,215
	Deferred rent, current			7,226		—
	Accrued payroll			—		126,910
	Consulting and other costs			—		5,031
	Vacation pay			—		5,690
	Interest payable			—		24,276
			$	1,645,258	$	815,239
	-1	Under the terms of a research agreement with Primomed, the Company received grant funds that will be used to offset
		certain costs under the MIN-301 development program.
	-2	Accounts payable and accrued professional fees at December 31, 2013 included $0.4 million incurred in
		connection with the preparation of the Company’s IPO.

Net_Loss_Per_Share_of_Common_S1

Net Loss Per Share of Common Stock (Tables)	12 Months Ended
	Dec. 31, 2014
Earnings Per Share [Abstract]
Computation of Basic and Diluted Loss Per Share	The following table sets forth the computation of basic and diluted loss per share for common stockholders:
		Year Ended December 31,
		2014			2013
	Net loss	$	(56,901,439	)	$	(3,262,005	)
	Weighted average shares of common stock outstanding		12,724,395			4,186,104
	Net loss per share of common stock – basic and diluted	$	(4.47	)	$	(0.78	)
Securities Excluded from Calculation of Weighted Average Shares Outstanding as their Effect is Antidilutive	The following securities outstanding at December 31, 2014 and 2013 have been excluded from the calculation of weighted average shares outstanding as their effect on the calculation of loss per share is antidilutive:
		December 31,			December 31,
		2014			2013
	Non-vested stock issued (see Note 9 – Stockholders’ Equity)		—			1,275,530
	Common stock options		2,076,558			646,759

Debt_Tables

Debt (Tables)	12 Months Ended
	Dec. 31, 2014
Debt Disclosure [Abstract]
Schedule of Convertible Promissory Notes and Debt Discount	As of December 31, 2014 and 2013, the convertible promissory notes and debt discount are as follows:
		December 31, 2014		December 31, 2013
	Convertible promissory notes	$	—	$	1,973,500
	Debt discount		—		(1,937,269	)
	Foreign exchange effect on Euro denominated notes		—		22,039
		$	—	$	58,270

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2014
Stockholders Equity Note [Abstract]
Summary of Common Shares Issued in Exchange for Nonrecourse Notes	The following is a summary of common shares issued in exchange for nonrecourse notes for the years December 31, 2014 and 2013:
		Common Shares
	Outstanding December 31, 2012		821,429
	Assumed in Sonkei merger		426,176
	Issued		27,925
	Outstanding December 31, 2013		1,275,530
	Repurchased		-348,926
	Shares vested June 30, 2014		926,604

Stock_Option_Plan_Tables

Stock Option Plan (Tables)	12 Months Ended
	Dec. 31, 2014
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Schedule of Stock Option Activity	Stock option activity under the Plan for the years ended December 31, 2014 and 2013 is as follows:
					Weighted-Average
		Stock Options			Exercise Price
	Outstanding January 1, 2013		—			—
	Granted		646,759		$	9.49
	Outstanding December 31, 2013		646,759		$	9.49
	Granted		1,975,151		$	6.05
	Forfeited		(545,352	)	$	7.89
	Outstanding December 31, 2014		2,076,558		$	6.64
	Exercisable December 31, 2014		1,286,890		$	6.91

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Schedule of Deferred Tax Assets and Liabilities	Net deferred tax assets (liabilities) as of December 31, 2014 and 2013 consist of the following:
		2014			2013
	Deferred tax assets:
	Net operating loss carryforwards	$	11,384,959		$	5,886,683
	Research and development tax credits		145,115			141,231
	Capitalized research and development costs		3,067,414			—
	Stock-based compensation		2,961,324			88,368
	Deferred start-up and license costs		11,991,001			2,705,248
	Net deferred tax assets		29,549,813			8,821,530
	Valuation allowance		(29,549,813	)		(8,821,530	)
	Net deferred tax assets	$	—		$	—
	Deferred tax liabilities:
	In-process research and development		(13,433,760	)		(7,588,600	)
	Net deferred tax liabilities	$	(13,433,760	)	$	(7,588,600	)
Schedule of Effective Income Tax Rate Reconciliation	A reconciliation between the Company’s effective tax rate and the federal statutory rate for the years ended December 31, 2014 and 2013 are as follows:
		2014			2013
	Federal statutory rate		(34.00	%)		(34.00	%)
	Permanent differences		4.27	%		(2.49	%)
	State income taxes		(4.62	%)		(5.94	%)
	Valuation allowance		34.35	%		42.43	%
	Effective tax rate		0	%		0	%

Quarterly_Results_Unaudited_Ta

Quarterly Results (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2014
Quarterly Financial Information Disclosure [Abstract]
Schedule of Quarterly Financial Information
		Three Months Ended
		31-Mar-14			30-Jun-14			30-Sep-14			31-Dec-14
		(in thousands, except per share data)
	Total revenues	$	-		$	-		$	-		$	-
	Operating loss		(2,623	)		(17,650	)		(27,151	)		(7,446	)
	Net loss		(2,938	)		(19,366	)		(27,155	)		(7,442	)
	Loss per share, basic and diluted	$	(0.43	)	$	(2.55	)	$	(1.53	)	$	(0.40	)
		Three Months Ended
		31-Mar-13			30-Jun-13			30-Sep-13			31-Dec-13
		(in thousands, except per share data)
	Total revenues	$	-		$	-		$	-		$	-
	Operating loss		(271	)		(379	)		(482	)		(2,043	)
	Net loss		(271	)		(376	)		(488	)		(2,127	)
	Loss per share, basic and diluted	$	(0.08	)	$	(0.10	)	$	(0.12	)	$	(0.41	)

Recovered_Sheet1

NATURE OF OPERATIONS AND LIQUIDITY - Additional Information (Details) (USD $)	0 Months Ended	1 Months Ended	0 Months Ended		1 Months Ended
	Jul. 07, 2014	Jan. 31, 2015	Mar. 18, 2015	Feb. 12, 2014	Jul. 31, 2014	Dec. 31, 2014	Dec. 31, 2013	Jan. 16, 2015	Feb. 11, 2014
Nature Of Operations And Liquidity [Line Items]
Accumulated deficit						($74,731,230)	($17,829,791)
Net proceeds from sale of common stock, net of underwriting discount	55,000,000
Subsequent Event | Term Loan
Nature Of Operations And Liquidity [Line Items]
Amount drew dawn during period		10,000,000
Shares of common stock to purchase by warrant								40,790
Subsequent Event | Loan and Security Agreement | Term Loan
Nature Of Operations And Liquidity [Line Items]
Amount drew dawn during period		10,000,000
Subsequent Event | Private Placement
Nature Of Operations And Liquidity [Line Items]
Net proceeds from sale of common stock, net of underwriting discount			28,800,000
Shares of common stock to purchase by warrant			6,281,661
Mitsubishi | Co-development and License Agreement | MIN-202
Nature Of Operations And Liquidity [Line Items]
Payment of initial upfront license fee	$22,000,000			$22,000,000	$22,000,000
Mind-NRG
Nature Of Operations And Liquidity [Line Items]
Share capital acquired (as a percent)									100.00%

Recovered_Sheet2

SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)

12 Months Ended

1 Months Ended

12 Months Ended

12 Months Ended

0 Months Ended

1 Months Ended

Dec. 31, 2014

Dec. 31, 2013

Jul. 07, 2014

Nov. 30, 2013

Dec. 31, 2014

Dec. 31, 2013

Jul. 07, 2014

Dec. 31, 2013

Nov. 06, 2013

Nov. 06, 2013

Dec. 31, 2013

Dec. 31, 2013

Nov. 12, 2013

Nov. 12, 2013

Dec. 31, 2014

Dec. 31, 2013

Jul. 07, 2014

Feb. 12, 2014

Jul. 31, 2014

Dec. 31, 2014

USD ($)

USD ($)

USD ($)

Convertible Promissory Notes

Convertible Promissory Notes

Convertible Promissory Notes

Convertible Promissory Notes

Convertible Promissory Notes

Convertible Promissory Notes

Convertible Promissory Notes

Convertible Promissory Notes

Convertible Promissory Notes

Convertible Promissory Notes

Convertible Promissory Notes

In-Process Research and Development

In-Process Research and Development

Mitsubishi

Mitsubishi

Mitsubishi

Mitsubishi

USD ($)

USD ($)

USD ($)

EUR (€)

USD ($)

EUR (€)

Sonkei

Sonkei

Sonkei

Sonkei

USD ($)

USD ($)

Co-development and License Agreement

Co-development and License Agreement

Co-development and License Agreement

Co-development and License Agreement

USD ($)

EUR (€)

USD ($)

EUR (€)

MIN-202

MIN-202

MIN-202

MIN-202

USD ($)

USD ($)

USD ($)

USD ($)

Significant Accounting Policies [Line Items]

Payment of initial upfront license fee

$22,000,000

$22,000,000

$22,000,000

Accrued collaborative expenses

1,222,420

1,222,420

Asset Impairment Charges

0

0

Interest or penalties related to income taxes

0

0

Equipment estimated useful life

3 years

Impairment of Long-Lived Assets

0

0

Impairment of goodwill

0

0

Conversion of promissory notes due date

2014-07

Face value

1,300,000

1,300,000

680,000

518,519

680,000

518,519

Accrued interest

24,276

15,671

8,605

Fair value of convertible promissory notes

2,000,000

Carrying value of convertible promissory notes

58,270

Interest rate (as a percent)

8.00%

8.00%

8.00%

8.00%

8.00%

8.00%

Derivative liability

10,093

10,093

0

9,976

Remaining term

7 months

6 months

Discount rate (as a percent)

8.00%

8.00%

Change in fair value of the derivative liability

117

Conversion price (in dollars per share)

$6

$3.50

€ 3.50

$3.50

€ 3.50

Unamortized debt discount

1,937,269

2,000,000

2,000,000

Amortization of debt discount recorded as interest expense

$1,952,309

$36,231

$2,000,000

$36,231

Recovered_Sheet3

SIGNIFICANT ACCOUNTING POLICIES - Fair Value of Liabilities Measured on Recurring Basis and Determined by Valuation Techniques (Details) (Fair Value, Measurements, Recurring, USD $)	Dec. 31, 2013
In Thousands, unless otherwise specified
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Derivative liability:	$10
Fair Value, Inputs, Level 3
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Derivative liability:	$10

BUSINESS_COMBINATIONS_MindNRG_

BUSINESS COMBINATIONS - Mind-NRG Acquisition - Additional Information (Details) (Mind-NRG, USD $)	0 Months Ended
In Millions, except Share data, unless otherwise specified	Feb. 11, 2014
Mind-NRG
Business Acquisition [Line Items]
Number of shares of common stock	1,481,583
Aggregate consideration	$16.50
Estimated fair value (in dollars per share)	$11.17
Share capital acquired (as a percent)	100.00%

BUSINESS_COMBINATIONS_Aggregat

BUSINESS COMBINATIONS - Aggregate Consideration Allocated to Assets Acquired and Liabilities Assumed of Mind-NRG Acquisition (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Assets acquired and liabilities assumed based on estimated fair values
Goodwill	$14,869,399	$7,918,387
Mind-NRG
Assets acquired and liabilities assumed based on estimated fair values
Cash		1,167,869
Other assets		71,130
Goodwill		7,076,412
Deferred tax liability		-5,970,560
Accrued expenses		-321,417
Total		16,541,834
Mind-NRG | In-Process Research and Development
Assets acquired and liabilities assumed based on estimated fair values
In-process research and development		15,200,000
Mind-NRG | ProteoSys
Assets acquired and liabilities assumed based on estimated fair values
Milestone payable		($681,600)

BUSINESS_COMBINATIONS_Sonkei_M

BUSINESS COMBINATIONS - Sonkei Merger - Additional Information (Details)

Dec. 31, 2013

Nov. 06, 2013

Dec. 31, 2014

Dec. 31, 2013

Nov. 12, 2013

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2013

Nov. 12, 2013

Nov. 12, 2013

Nov. 12, 2013

Nov. 12, 2013

Dec. 31, 2013

Convertible Promissory Notes

Convertible Promissory Notes

Common Stock

Common Stock

Sonkei

Sonkei

Sonkei

Sonkei

Sonkei

Sonkei

Sonkei

Sonkei

Sonkei

USD ($)

USD ($)

USD ($)

USD ($)

Convertible Promissory Notes

Convertible Promissory Notes

Convertible Promissory Notes

Convertible Promissory Notes

Nonemployee Holding Common Stock With Nonrecourse Note

Common Stock

General and Administrative Expenses

USD ($)

EUR (€)

USD ($)

EUR (€)

USD ($)

Business Acquisition [Line Items]

Conversion ratio

0.383

Number of shares of common stock

2,423,368

Number of shares held

1,112,500

Number of shares issued

426,176

Issuance of shares for business acquisition (in shares)

1,481,583

1,997,192

1,997,192

Aggregate consideration

$18,900,000

Estimated fair value (in dollars per share)

$9.49

Merger Expenses

14,000

Principal amount

1,300,000

1,300,000

680,000

518,519

680,000

518,519

Deferred tax liability

7,463,200

-100,000

Net operating losses

$5,300,000

BUSINESS_COMBINATIONS_Aggregat1

BUSINESS COMBINATIONS - Aggregate Consideration Allocated to Assets Acquired and Liabilities Assumed of Sonkei Merger (Details)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2013	Nov. 06, 2013	Dec. 31, 2014	Nov. 12, 2013	Nov. 12, 2013	Dec. 31, 2013	Dec. 31, 2013	Nov. 12, 2013	Nov. 12, 2013
	USD ($)	USD ($)	Convertible Promissory Notes	Convertible Promissory Notes	Sonkei	Sonkei	Sonkei	Sonkei	Sonkei	Sonkei	Sonkei
			USD ($)	USD ($)	USD ($)	USD ($)	In-Process Research and Development	Convertible Promissory Notes	Convertible Promissory Notes	Convertible Promissory Notes	Convertible Promissory Notes
							USD ($)	USD ($)	EUR (€)	USD ($)	EUR (€)
Assets acquired and liabilities assumed based on estimated fair values
Cash						$631,478
Goodwill	14,869,399	7,918,387				7,792,987
In-process research and development							19,000,000
Accrued expenses						-334,423
Derivative liability						-3,476
Deferred tax liability					100,000	-7,463,200
Convertible promissory notes (see Note 7)			-1,300,000	-1,300,000				-680,000	-518,519	-680,000	-518,519
Total						$18,943,366

BUSINESS_COMBINATIONS_Pro_Form

BUSINESS COMBINATIONS - Pro Forma Results (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Unaudited pro forma financial information
Operating loss	($57,354,314)	($5,541,476)
Loss per share	($4.51)	($0.74)

Recovered_Sheet4

ACCRUED EXPENSES AND OTHER LIABILITIES - Accrued Expenses and Other Liabilities (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Payables And Accruals [Abstract]
Accrued severance	$636,033
Research and development costs	415,595	58,117
Accrued bonus	327,960
Primomed research funding	127,209
Accrued excise and franchise taxes	76,885
Professional fees	54,350	595,215
Deferred rent, current	7,226
Accrued payroll		126,910
Consulting and other costs		5,031
Vacation pay		5,690
Interest payable		24,276
Accrued expenses and other liabilities	$1,645,258	$815,239

Recovered_Sheet5

ACCRUED EXPENSES AND OTHER LIABILITIES - Accrued Expenses and Other Liabilities (Parenthetical) (Details) (USD $)	Dec. 31, 2013
In Millions, unless otherwise specified
Payables And Accruals [Abstract]
Cost incurred in connection with the preparation for the Company's IPO included in accrued professional fees	$0.40

Recovered_Sheet6

NET LOSS PER SHARE OF COMMON STOCK - Computation of Basic and Diluted Loss Per Share (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Earnings Per Share [Abstract]
Net loss	($56,901,439)	($3,262,005)
Weighted average shares of common stock outstanding	12,724,395	4,186,104
Net loss per share of common stock b basic and diluted	($4.47)	($0.78)

Recovered_Sheet7

NET LOSS PER SHARE OF COMMON STOCK - Securities Excluded from Calculation of Weighted Average Shares Outstanding as their Effect is Antidilutive (Details)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Non-Vested Stock Issued
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Securities outstanding excluded from the calculation of weighted average shares outstanding		1,275,530
Common Stock Options
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Securities outstanding excluded from the calculation of weighted average shares outstanding	2,076,558	646,759

LICENSE_AGREEMENTS_Additional_

LICENSE AGREEMENTS - Additional Information (Details) (Mitsubishi, License Agreement, USD $)	1 Months Ended	4 Months Ended	12 Months Ended
In Millions, unless otherwise specified	Jan. 31, 2014	Dec. 31, 2007	Dec. 31, 2010	Dec. 31, 2008	Aug. 30, 2007	Sep. 01, 2008
	item
MIN-101
License Agreement
Payment of initial upfront license fee		$1	$0.50	$0.50
Potential milestone payments upon achievement of milestone	0.5
Number of development milestones required	1
MIN-101 | Maximum
License Agreement
Potential milestone payments upon achievement of milestone	47.5				57.5
Additional Products | Maximum
License Agreement
Potential milestone payments upon achievement of milestone					59.5
MIN-117
License Agreement
Term of extension of the agreement	1 year
Potential extension payment	0.5
MIN-117 | Maximum
License Agreement
Potential milestone payments upon achievement of milestone	$47.50					$57.50

DEBT_Loans_Payable_Additional_

DEBT - Loans Payable - Additional Information (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Jul. 07, 2014	31-May-14	Feb. 11, 2014
Debt
Percentage of interest rate on loan		8.00%
Balance outstanding	$1,400,000		$600,000
Accrued interest paid	15,233
Bridge Loan
Debt
Maximum drawdown amount			1,000,000	600,000
Percentage of interest rate on loan			8.00%	8.00%
Accrued interest paid	11,000
Bridge Loan | Interest Income Expense
Debt
Interest expense	$16,000
Bridge Loan | Under Standard Terms of Default
Debt
Percentage of interest rate on loan			11.00%	11.00%

DEBT_Convertible_Promissory_No

DEBT - Convertible Promissory Notes - Additional Information (Details)

0 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

12 Months Ended

0 Months Ended

Jul. 07, 2014

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2014

Nov. 30, 2013

Dec. 31, 2013

Dec. 31, 2013

Jul. 07, 2014

Nov. 06, 2013

Nov. 06, 2013

Dec. 31, 2014

Dec. 31, 2013

Nov. 12, 2013

Nov. 12, 2013

Dec. 31, 2013

Dec. 31, 2013

Nov. 06, 2013

USD ($)

USD ($)

USD ($)

Interest Income Expense

Convertible Promissory Notes

Convertible Promissory Notes

Convertible Promissory Notes

Convertible Promissory Notes

Convertible Promissory Notes

Convertible Promissory Notes

Convertible Promissory Notes

Convertible Promissory Notes

Convertible Promissory Notes

Convertible Promissory Notes

Convertible Promissory Notes

Convertible Promissory Notes

Under Standard Terms of Default

USD ($)

USD ($)

EUR (€)

USD ($)

USD ($)

EUR (€)

Interest Income Expense

Interest Income Expense

Sonkei

Sonkei

Sonkei

Sonkei

Convertible Promissory Notes

USD ($)

USD ($)

USD ($)

EUR (€)

USD ($)

EUR (€)

Debt

Percentage of interest rate on loan

8.00%

8.00%

8.00%

8.00%

8.00%

8.00%

8.00%

11.00%

Principal amount

$1,300,000

$1,300,000

$680,000

€ 518,519

$680,000

€ 518,519

Conversion price (in dollars per share)

$6

$3.50

€ 3.50

$3.50

€ 3.50

Conversion of debt to common stock (in shares)

352,000

Convertible promissory notes, maturity date

30-Jun-14

30-Jun-14

Percentage multiplied to price per share paid by the Investors for each share of common stock to determine conversion price

80.00%

80.00%

Derivative liability

10,093

10,093

0

9,976

Discount rate (as a percent)

8.00%

8.00%

8.00%

Remaining term

7 months

6 months

6 months

Change in fair value of derivative

10,093

-117

10,093

Unamortized debt discount

1,937,269

2,000,000

2,000,000

Interest expense

$2,000,000

$59,000

DEBT_Convertible_Promissory_No1

DEBT - Convertible Promissory Notes - Convertible Promissory Notes and Debt Discount (Details) (USD $)	Dec. 31, 2013
Debt Disclosure [Abstract]
Convertible promissory notes	$1,973,500
Debt discount	-1,937,269
Foreign exchange effect on Euro denominated notes	22,039
Convertible promissory notes, net	$58,270

Recovered_Sheet8

CO-DEVELOPMENT AND LICENSE AGREEMENT - Additional Information (Details) (USD $)	12 Months Ended		0 Months Ended		1 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Jul. 07, 2014	Feb. 12, 2014	Jul. 31, 2014
Co-development and license agreement
Accrued collaborative expenses	$1,222,420
Payment of development costs	11,961,865	2,466,490
Common Stock Purchase Agreement
Co-development and license agreement
Issuance of common stock pursuant to an initial public offering and concurrent private placements, net of issuance costs (in shares)			3,284,353
Net proceeds from issuance of common stock			19,700,000
Common Stock Purchase Agreement | Maximum
Co-development and license agreement
Common stock agreed to be issued (in shares)				26,000,000
MIN-202 | Co-development and License Agreement | Phase Ib Clinical Trials | Maximum
Co-development and license agreement
Share of aggregate development cost following completion of Phase Ib clinical trials and animal toxicology studies				5,000,000
MIN-202 | Co-development and License Agreement | Phase II Clinical Trials | Maximum
Co-development and license agreement
Share of aggregate development cost following completion of Phase Ib clinical trials and animal toxicology studies				24,000,000
Mitsubishi | MIN-202 | Co-development and License Agreement
Co-development and license agreement
Payment of initial upfront license fee			22,000,000	22,000,000	22,000,000
Percentage of development costs related to joint development of products				40.00%
Period within which agreement is terminated related to Phase Ib clinical trials milestone				45 days
Termination fee related to Phase Ib clinical trial milestone				3,000,000
Accrued collaborative expenses	1,222,420
Payment of development costs	$1,200,000

STOCKHOLDERS_EQUITY_Reverse_St

STOCKHOLDERS' EQUITY - Reverse Stock Split - Additional Information (Details) (USD $)	0 Months Ended
	Jun. 09, 2014	Dec. 31, 2014	Dec. 31, 2013
Stockholders Equity Note [Abstract]
Reverse stock split ratio	3.5
Total number of authorized shares	225,000,000
Common stock, shares authorized	125,000,000	125,000,000	125,000,000
Common stock, par value (in dollars per share)	$0.00	$0.00	$0.00
Preferred stock, shares authorized	100,000,000	100,000,000	100,000,000
Preferred stock, par value (in dollars per share)	$0.00	$0.00	$0.00

STOCKHOLDERS_EQUITY_Initial_Pu

STOCKHOLDERS' EQUITY - Initial Public Offering and Concurrent Private Placements - Additional Information (Details) (USD $)	12 Months Ended	0 Months Ended
	Dec. 31, 2014	Jul. 07, 2014	Jul. 29, 2014
Stockholders Equity [Line Items]
Stock issuance expenses	$3,159,835
Common Stock Purchase Agreement
Stockholders Equity [Line Items]
Sale of common stock (in shares)		3,284,353
Net proceeds from sale of common stock		19,700,000
IPO
Stockholders Equity [Line Items]
Sale of common stock (in shares)		5,454,545
Share price (in dollars per share)		$6
Aggregate proceeds from sale of common stock		32,700,000
Net proceeds from sale of common stock		28,200,000
Stock issuance expenses		3,100,000
Over-Allotment Option
Stockholders Equity [Line Items]
Sale of common stock (in shares)			160,993
Share price (in dollars per share)			$6
Private Placement
Stockholders Equity [Line Items]
Sale of common stock (in shares)		666,666
Share price (in dollars per share)		$6
Aggregate proceeds from sale of common stock		4,000,000
Net proceeds from sale of common stock		3,700,000
Private Placement | Common Stock Purchase Agreement
Stockholders Equity [Line Items]
Sale of common stock (in shares)		3,284,353
Net proceeds from sale of common stock		$19,700,000

STOCKHOLDERS_EQUITY_Common_Sto

STOCKHOLDERS' EQUITY - Common Stock Issued for Nonrecourse Notes - Additional Information (Details)

0 Months Ended

12 Months Ended

12 Months Ended

0 Months Ended

1 Months Ended

12 Months Ended

12 Months Ended

Jul. 07, 2014

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2014

Jun. 30, 2014

Mar. 31, 2014

Apr. 26, 2012

Mar. 31, 2014

Dec. 31, 2013

Dec. 31, 2014

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

USD ($)

Common Stock

Nonrecourse Note

Nonrecourse Note

Nonrecourse Note

Nonrecourse Note

Nonrecourse Note

Nonrecourse Note

Nonrecourse Note

Nonrecourse Note

Nonrecourse Note

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Sonkei

Sonkei

USD ($)

EUR (€)

Stockholders Equity [Line Items]

Stock issued in settlement of nonrecourse notes

352,000

352,000

821,429

27,925

1,112,500

1,112,500

Face value

$4,700,000

$3,058,026

$4,700,000

$97,737

$1,500,000

€ 1,119,017

Share price (in dollars per share)

$13.51

$3.71

$13.51

Interest rate (as a percent)

8.00%

0.19%

0.19%

0.19%

Number of shares remitted

348,926

348,926

Number of stock options (in shares)

2,076,558

646,759

1,300,000

1,300,000

Exercise price of stock options

4,700,000

Stock issued

926,604

926,604

1,275,530

821,429

Exercise price of non-vested stock

0

Stock based compensation expense

$500,000

$10,500,000

STOCKHOLDERS_EQUITY_Common_Sha

STOCKHOLDERS' EQUITY - Common Shares Issued in Exchange for Nonrecourse Notes (Details)	0 Months Ended	12 Months Ended
	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013
Stockholders Equity [Line Items]
Shares vested at the end of the period (in shares)		926,604
Common Stock
Stockholders Equity [Line Items]
Assumed in Sonkei merger		1,481,583	1,997,192
Common Stock | Nonrecourse Note
Stockholders Equity [Line Items]
Outstanding at the beginning of the period (in shares)		1,275,530	821,429
Assumed in Sonkei merger			426,176
Repurchased	-348,926	-348,926
Issued (in shares)			27,925
Outstanding at the end of the period (in shares)	926,604		1,275,530

STOCKHOLDERS_EQUITY_Common_Sto1

STOCKHOLDERS' EQUITY - Common Stock Issued to Consultant - Additional Information (Details) (USD $)	12 Months Ended		0 Months Ended
	Dec. 31, 2013	Dec. 31, 2014	Dec. 20, 2013
Stockholders Equity [Line Items]
Issuance of common stock to a consultant	$232,534
Common Stock
Stockholders Equity [Line Items]
Sale of common stock (in shares)		9,566,557
Issuance of common stock to a consultant	2
Common Stock | Consultant
Stockholders Equity [Line Items]
Sale of common stock (in shares)			24,516
Share price (in dollars per share)			$8.58
Issuance of common stock to a consultant			$232,534

STOCK_OPTION_PLAN_Additional_I

STOCK OPTION PLAN - Additional Information (Details) (USD $)	0 Months Ended	12 Months Ended		0 Months Ended
	Jul. 07, 2014	Dec. 31, 2014	Dec. 31, 2013	1-May-14	Dec. 20, 2013	Apr. 30, 2014	Jun. 30, 2014
				item
Assumptions used in fair value of each stock option to purchase common stock using the Black-Scholes option pricing model
Dividend yield (as a percent)	0.00%	0.00%
Risk free interest rate (as a percent)	1.90%
Volatility (as a percent)	113.00%
Additional disclosure
Stock based compensation expense		$500,000
Granted (in dollars per share)		$6.05	$9.49
Vesting period		3 years
Total unrecognized compensation costs related to non-vested awards (in dollars)		4,000,000
Period over which unrecognized compensation costs related to non-vested awards is expected to be recognized		3 years 9 months
Weighted average contractual term of the options outstanding		9 years 4 months 24 days
Intrinsic value of outstanding stock options (in dollars)		37,000
Stock Options
Granted (in shares)	480,103	1,975,151	646,759
Employment Contract
Additional disclosure
Number of agreements				2
Vest Over Four Year
Stock Options
Granted (in shares)	352,590
Vest Over Three Year
Stock Options
Granted (in shares)	127,513
Employees And Directors
Additional disclosure
Vesting period		4 years
Minimum
Assumptions used in fair value of each stock option to purchase common stock using the Black-Scholes option pricing model
Expected term	6 years
Maximum
Assumptions used in fair value of each stock option to purchase common stock using the Black-Scholes option pricing model
Expected term	6 years 3 months
Stock Option | Award Vested Over Four Year Beginning from November 12 2013 | Employment Contract
Additional disclosure
Number of agreements		3
2013 Equity Incentive Plan
Stock Option Plan
Number of shares of common stock reserved for issuance						3,543,754
2013 Equity Incentive Plan | Awards Fully Vested and Exercisable upon Effective Date of IPO Registration
Stock Options
Granted (in shares)					20,089
2013 Equity Incentive Plan | Stock Option
Stock Option Plan
Term of share-based award						10 years
Assumptions used in fair value of each stock option to purchase common stock using the Black-Scholes option pricing model
Risk free interest rate, minimum (as a percent)					1.90%
Risk free interest rate, maximum (as a percent)					2.90%
Volatility, minimum (as a percent)					102.00%
Volatility, maximum (as a percent)					107.00%
Dividend yield (as a percent)					0.00%
Fair value of common stock on grant date (in dollars per share)					9.49
Additional disclosure
Stock based compensation expense		2,100,000	400,000
2013 Equity Incentive Plan | Stock Option | Awards Fully Vested and Exercisable upon Effective Date of IPO Registration
Additional disclosure
Stock based compensation expense		200,000
2013 Equity Incentive Plan | Stock Option | Minimum
Assumptions used in fair value of each stock option to purchase common stock using the Black-Scholes option pricing model
Expected term					5 years 9 months 18 days
2013 Equity Incentive Plan | Stock Option | Maximum
Assumptions used in fair value of each stock option to purchase common stock using the Black-Scholes option pricing model
Expected term					10 years
Amended And Restated Equity Incentive Plan
Assumptions used in fair value of each stock option to purchase common stock using the Black-Scholes option pricing model
Fair value of common stock on grant date (in dollars per share)		$5.63
Additional disclosure
Stock based compensation expense							2,700,000
Granted (in dollars per share)							$6
Amended And Restated Equity Incentive Plan | Award Vested on Grant Date
Stock Options
Granted (in shares)							539,116
Amended And Restated Equity Incentive Plan | Award Vested Over Four Year Beginning from November 12 2013
Stock Options
Granted (in shares)		955,932
Amended And Restated Equity Incentive Plan | Stock Option
Assumptions used in fair value of each stock option to purchase common stock using the Black-Scholes option pricing model
Expected term							6 years 3 months
Dividend yield (as a percent)							0.00%
Fair value of common stock on grant date (in dollars per share)							$6
Risk free interest rate (as a percent)							1.90%
Volatility (as a percent)							113.00%
Additional disclosure
Vesting period		4 years
Amended And Restated Equity Incentive Plan | Stock Option | Award Vested Over Four Year Beginning from November 12 2013
Assumptions used in fair value of each stock option to purchase common stock using the Black-Scholes option pricing model
Expected term		6 years 3 months
Dividend yield (as a percent)		0.00%
Fair value of common stock on grant date (in dollars per share)		$6
Risk free interest rate (as a percent)		1.90%
Volatility (as a percent)		113.00%
Additional disclosure
Stock based compensation expense		$1,900,000

STOCK_OPTION_PLAN_Stock_Option

STOCK OPTION PLAN - Stock Option Activity (Details) (USD $)	0 Months Ended	12 Months Ended
	Jul. 07, 2014	Dec. 31, 2014	Dec. 31, 2013
Stock Options
Outstanding at the beginning of period (in shares)		646,759
Granted (in shares)	480,103	1,975,151	646,759
Forfeited (in shares)		-545,352
Outstanding at the end of the period (in shares)		2,076,558	646,759
Exercisable at the end of the period (in shares)		1,286,890
Weighted-Average Exercise Price
Outstanding at the beginning of period (in dollars per share)		$9.49
Granted (in dollars per share)		$6.05	$9.49
Forfeited (in dollars per share)		$7.89
Outstanding at the end of the period (in dollars per share)		$6.64	$9.49
Exercisable at the end of the period (in dollars per share)		$6.91

INCOME_TAXES_Net_Deferred_Tax_

INCOME TAXES - Net Deferred Tax Assets(Liabilities) (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Deferred tax assets:
Net operating loss carryforwards	$11,384,959	$5,886,683
Research and development tax credits	145,115	141,231
Capitalized research and development costs	3,067,414
Stock-based compensation	2,961,324	88,368
Deferred start-up and license costs	11,991,001	2,705,248
Net deferred tax assets	29,549,813	8,821,530
Valuation allowance	-29,549,813	-8,821,530
Net deferred tax assets	0	0
Deferred tax liabilities:
In-process research and development	-13,433,760	-7,588,600
Net deferred tax liabilities	($13,433,760)	($7,588,600)

INCOME_TAXES_Reconciliation_Be

INCOME TAXES - Reconciliation Between Effective Tax Rate and Federal Statutory Rate (Details)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Income Tax Disclosure [Abstract]
Federal statutory rate	-34.00%	-34.00%
Permanent differences	4.27%	-2.49%
State income taxes	-4.62%	-5.94%
Valuation allowance	34.35%	42.43%
Effective tax rate	0.00%	0.00%

INCOME_TAXES_Additional_Inform

INCOME TAXES - Additional Information (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Nov. 12, 2013
Operating Loss Carryforwards [Line Items]
Increase ( decrease) in valuation allowance on net deferred tax assets	$20.70	$3.30
Sonkei
Operating Loss Carryforwards [Line Items]
Net operating losses			5.3
Net operating loss expiration period	20 years
Federal
Operating Loss Carryforwards [Line Items]
Net operating losses	26.4
Operating losses, year begin to expire	2027
Federal | Federal research and development
Operating Loss Carryforwards [Line Items]
Federal research and development credits	0.1
Federal research and development credits expiration year	2028
New jersey
Operating Loss Carryforwards [Line Items]
Net operating losses	10.4
Operating losses, year begin to expire	2015
Massachusetts
Operating Loss Carryforwards [Line Items]
Net operating losses	11
Operating losses, year begin to expire	2024
Switzerland
Operating Loss Carryforwards [Line Items]
Net operating losses	$4.90
Operating losses, year begin to expire	2018

COMMITMENTS_Additional_Informa

COMMITMENTS - Additional Information (Details) (USD $)	1 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014
	sqft
Commitments And Contingencies Disclosure [Abstract]
Area of office space	4,043
Estimated annual rent payable	$0.10
Lease term	2 years

RELATED_PARTY_TRANSACTIONS_Add

RELATED PARTY TRANSACTIONS - Additional Information (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Related Party Transaction [Line Items]
Reimbursements revenue	$268,990	$111,351
Investor
Related Party Transaction [Line Items]
Accounting and other services expenses per year		60,000
Related party expenses	35,000	65,000
Investor | Sonkei
Related Party Transaction [Line Items]
Accounting and other services expenses per year		5,000
Certain stockholders
Related Party Transaction [Line Items]
Related party expenses	$247,400	$538,996

QUARTERLY_RESULTS_Unaudited_Sc

QUARTERLY RESULTS (Unaudited) - Schedule of Quarterly Financial Information (Details) (USD $)	3 Months Ended								12 Months Ended
	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013
Quarterly Financial Information Disclosure [Abstract]
Operating loss	($7,446,000)	($27,151,000)	($17,650,000)	($2,623,000)	($2,043,000)	($482,000)	($379,000)	($271,000)	($54,870,431)	($3,174,979)
Net loss	($7,442,000)	($27,155,000)	($19,366,000)	($2,938,000)	($2,127,000)	($488,000)	($376,000)	($271,000)
Loss per share, basic and diluted	($0.40)	($1.53)	($2.55)	($0.43)	($0.41)	($0.12)	($0.10)	($0.08)

SUBSEQUENT_EVENTS_Details

SUBSEQUENT EVENTS (Details) (USD $)

0 Months Ended

12 Months Ended

0 Months Ended

1 Months Ended

0 Months Ended

Jul. 07, 2014

Dec. 31, 2014

Mar. 31, 2016

Mar. 18, 2015

Jan. 16, 2015

Jan. 31, 2015

Jan. 02, 2015

Feb. 02, 2015

Jun. 09, 2014

Dec. 31, 2013

Mar. 13, 2015

Jan. 01, 2015

Tranche

Person

Subsequent Event [Line Items]

Interest rate (as a percent)

8.00%

Common stock, par value (in dollars per share)

$0.00

$0.00

$0.00

Sale of common stock, price per share

$3.50

Net proceeds from sale of common stock, net of underwriting discount

$55,000,000

Warrants expiration date

18-Mar-17

Mind-NRG, SA

Subsequent Event [Line Items]

Percentage of ownership after each of common stock purchase agreement closings

65.00%

Term Loan

Subsequent Event [Line Items]

Term loan, interest rate term

The Term B Loans will bear interest at a fixed rate per annum of the greater of (i) 7.05% or (ii) the sum of (a) the prime rate reported in The Wall Street Journal three (3) business days prior to the funding date of the Term B Loans, plus (b) 3.80%.

Number of installments period

30 months

Extended interest period for debt instrument

6 months

Reduced repayment period for debt instrument

6 months

Term loans maturity date

1-Aug-18

Advance notice period to the lenders

30 days

Terms of loan prepayment fee

(i) 3% of the outstanding balance, if the loan is prepaid within twenty-four (24) months of the funding date, (ii), 2% of the outstanding balance, if the loan is prepaid between twenty-four (24) and thirty-six (36) months of the funding date and (iii) 1% of the outstanding balance, if the loan is prepaid thereafter (each, a bPrepayment Feeb)

Consecutive trading days

10 days

Expiration anniversary date of issuance

10 years

Term Loan | Scenario, Forecast

Subsequent Event [Line Items]

Aggregate principal amount

5,000,000

Interest rate (as a percent)

3.80%

Minimum percentage of interest rate on loan

7.05%

Subsequent Event | Warrant

Subsequent Event [Line Items]

Shares of common stock to purchase by warrant

6,281,661

Sale of stock price per warrant share

$0.13

Initial exercise price of warrants

$5.77

Subsequent Event | Private Placement

Subsequent Event [Line Items]

Shares of common stock to purchase by warrant

6,281,661

Sale of common stock, price per share

$4.81

Net proceeds from sale of common stock, net of underwriting discount

28,800,000

Percentage of penalties if file not timely

10.00%

Subsequent Event | Term Loan

Subsequent Event [Line Items]

Aggregate principal amount

15,000,000

Number of tranches

2

Amount drew dawn during period

10,000,000

Interest rate (as a percent)

7.05%

Facility fee payment

75,000

Final payment of term loan

4.45%

Extended interest of term loan

5.10%

Minimum capital requirement

30,000,000

Sale of equity securities

$20,000,000

Common stock, par value (in dollars per share)

$0.00

Aggregate number of shares of Common Stock issuable

2.25%

Shares of common stock to purchase by warrant

40,790

Common stock exercise price per share

$5.52

Subsequent Event | Term Loan | 24 months

Subsequent Event [Line Items]

Proportion of prepayment fees on outstanding balance

3.00%

Subsequent Event | Term Loan | Between 24 and 36 months

Subsequent Event [Line Items]

Proportion of prepayment fees on outstanding balance

2.00%

Subsequent Event | Term Loan | Prepaid Thereafter

Subsequent Event [Line Items]

Proportion of prepayment fees on outstanding balance

1.00%

Subsequent Event | 2013 Equity Incentive Plan

Subsequent Event [Line Items]

Shares authorized for issuance

4,281,333

Shares authorized for issuance

737,579

Increase in shares authorized for issuance as percentage of shares outstanding

4.00%

Stock options granted

10,000

Stock options exercise price

$6.11

Board of Directors | Subsequent Event | 2013 Equity Incentive Plan

Subsequent Event [Line Items]

Stock options granted

15,000

Stock options exercise price

$4.34

Number of Board Directors to purchase common shares

2